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“It is difficult to say what is impossible, for the dream of yesterday 
is the hope of today and the reality of tomorrow.” 
 


























To all the women and girls  









Loss of fertility as a potential side effect of anti-neoplastic treatments may have a 
significant negative impact on the survivors’ quality of life. Assisted reproductive 
technologies (ART) have been adapted and further developed for fertility preservation (FP) 
and fertility treatments in young women with cancer. The last three decades have seen 
impressive achievements in this field, with the rapid introduction and development of 
methods in clinical practice. Still, the data on outcomes and safety of FP are scarce, and 
numerous questions await answering.  
 
The four studies included in this thesis aimed to investigate: if a history of cancer may 
increase the risk of adverse perinatal outcomes in pregnancies achieved with donor oocytes 
(Study I), if return rates and utilization rates differ in patients with oncologic and non-
oncologic indications for FP, and if the trends in decisions regarding preferred FP-methods 
have changed over time (Study II), if current approaches to controlled ovarian stimulation 
aimed at FP in women with breast cancer are efficacious and safe (Study III) and if long-
term reproductive outcomes after breast cancer differ in women with and without FP (Study 
IV).  
 
Study I was a single-center cohort study, including 25 live births in 20 women with a 
history of cancer and 244 live births in 212 women without a history of cancer, all after 
treatments with donor oocytes. Higher rates of pre-eclampsia (adjusted odds ratio (aOR) 
2.79, 95% CI 1.07-7.34) and preterm birth (aOR 5.54, 95% CI 2.01-15.31) were observed 
in women with a history of cancer.  
 
Study II included data on 1254 women that underwent FP counseling due to oncologic and 
non-oncologic indications at Karolinska University Hospital during a 20-year long period 
(1998-2018). Oncologic indication for FP was associated with a slightly lower likelihood of 
returning for counseling (OR 0.72, 95% CI 0.51-1.0) and a significantly lower likelihood of 
returning for pregnancy attempt (OR 0.41, 95%CI 0.27-0.62), when compared to non-
oncologic FP indication. Among different FP methods, cryopreservation of unfertilized 
oocytes has become the preferred one in recent years, both by adult women (with or 




Study III was a multicenter study including data on FP counseling (n=610) and FP 
treatments (n=468) of women with breast cancer at six Swedish University Hospitals with 
programs for FP. In this study 380 cycles of controlled ovarian stimulation (COS) in 
gonadotropin-releasing hormone (GnRH) antagonist protocol were available for the final 
analysis. Three recently introduced approaches to COS in women with cancer aiming to 
increase the safety of the procedures were investigated: 1) the concurrent use of letrozole, 
2) the random start initiation of stimulation, and 3) the use of gonadotropin-releasing 
hormone agonist (GnRHa) for ovulation trigger instead of hCG trigger. The efficacy of 
these approaches, measured as the number of cryopreserved oocytes and embryos, was 
observed to be at least non-inferior compared to the standard GnRH antagonist protocols. 
Overall survival did not differ between women with versus without FP, and women in 
letrozole versus non-letrozole group.  
 
Study IV, a register-based nationwide cohort study, included 425 women with and 850 
women without FP history, all of them diagnosed with breast cancer at reproductive age. 
Rates of live births (aHR: 2.3, 95%CI: 1.6-3.3) and ART-treatments (aHR: 4.8, 95%CI: 
2.2-10.7) after breast cancer were higher among women that had undergone FP when 
compared to women without FP. FP exposure was not associated with any decrease in 
overall survival in this cohort.  
 
In conclusion, the findings suggest that the use of ART for FP and fertility treatment in 
eligible young women with cancer seems to be both safe and efficacious. Yet, some caution 
is warranted when interpreting the findings, since these studies were not randomized and 
women with cancer who undergo FP might be healthier, on average, than the women who 
do not (“healthy FP effect”). In women with a previous history of cancer that achieve 
pregnancy with donor oocytes, individual assessment of pregnancy risks and potential 
increased obstetric surveillance may be indicated. Further research investigating the risk of 
breast cancer-relapse in women undergoing FP, with additional measures taken to 
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“May your choices reflect your hopes, not your fears.” - Nelson Mandela 
 
Fertility – what’s in the word?  
The state of being fertile. 
From Latin fertilis, "bearing in abundance or fruitful”.  
Commonly understood as the ability to get pregnant, to produce offspring.  
 
Something that we usually take for granted, when young. 
Or may even suffer from, when unprepared for its power.  
A potential source of joy and happiness.  
Or a cause of existential crisis, when threatened or absent.  
Something very complex and delicate.   
Something worth to protect.  
 
In young people diagnosed with cancer, anti-neoplastic treatments pose a risk of damage to 
fertility. Though not always an issue of primary concern at the time of diagnosis, the 
inability to get children later in life may cause stress and sorrow.  
 
The field of fertility preservation (FP) is relatively new. For men, freezing of spermatozoa 
was described as early as the 18th century, but cryopreservation became feasible and 
practical first in the mid-1900s. For women, achievements of in-vitro fertilization (IVF) and 
the establishment of assisted reproductive technologies (ART) into clinical practice in the 
1970s became an important milestone. These techniques were gradually implemented for 
FP, with tremendous development during the last three decades.  
 
When this project started in 2015, the practice of FP for women with cancer was  
already established at six university hospitals in Sweden. According to the international and 
national guidelines, oncologists were encouraged to refer all young patients facing 
gonadotoxic therapies to fertility counseling. Available options of FP included 
cryopreservation of embryos, oocytes and ovarian tissue, with the latter still considered an 
experimental method. Women who developed ovarian failure as a side effect of cancer 
treatment could also have the option of attempting pregnancy with donated oocytes. Long-
term follow-up reports on FP efficacy and safety profile in women with cancer and on their 
obstetrical risk following ART treatments using donor oocytes were lacking. Therefore, the 
studies of this thesis were designed with some specific questions in mind:  
Is there any increased risk of adverse perinatal outcome in pregnancies achieved with 
donated oocytes in women previously treated for cancer? Have trends in FP-choices 
changed over time? Which protocols for ovarian stimulation in the population of women 
with breast cancer are most effective and safe?  What are the post-diagnosis birth rates in 
women with and without FP indicated by BC diagnosis? Does the history of FP affect 
prognosis for survival in women with BC? 
 
By providing answers to the questions above, the overall purpose of this thesis was to 
increase the knowledge on efficacy and safety of FP and fertility treatments in young 
women with cancer and, ultimately, to contribute to a better quality of life in this 
population. Well-defined strategies to secure a fair chance of biological parenthood in the 
future, after completing the treatments, may give strength and hope in difficult times of 
struggling with the disease. May knowledge and hope, not fear, guide choices regarding 





2.1 CANCER AND FERTILITY  
 
Worldwide, about 3-10% of patients diagnosed with cancer are younger than 40 years of 
age (1, 2). Though the burden of cancer across all ages combined is higher in males than 
females, women are affected more often than men during the reproductive years (3).   
 
Advances in early detection and improved treatment efficacy have led to a growing number 
of survivors. Consequently, specific concerns and needs of these patients have acquired 
high priority. Research has shown that fertility and reproduction issues are important to 
young cancer survivors, and iatrogenic infertility may have profound negative effects on 
their quality of life (4, 5).  Furthermore, there is evidence that most cancer survivors prefer 
biological parenthood to other options such as adoption or oocyte donation (6).  
 
2.1.1 The effect of cancer disease and its treatment on female fertility. 
 
Possible adverse effects of cancer disease and its treatment on female fertility depend on 
multiple factors (7):  
 
 age of the patient and her pre-treatment fertility status 
 type and stage of cancer disease 
 anatomic or vascular changes in the pelvic region due to surgery. 
 different modalities and combination of antineoplastic treatments: 
- dose and location of the fields of radiotherapy  
- type, dose and dose-intensity of chemotherapeutics  








Figure 1. Consequences of gonadotoxic treatments in women of fertile age.  
 
 
 (A) The primordial follicle population—the ovarian reserve—can be represented by a parabolic curve across the female 
lifespan in which activation or death of primordial ovarian follicles occurs progressively with each menstrual cycle, from 
puberty to the menopause. Reprinted from Wallace and Kelsey (8). (B–D) The growth of follicles with each cycle 
maintains hormonal balance necessary for overall women’s health. Gonadotoxic stress or treatment, such as chemotherapy 
or radiation therapy (red bar across all panels), induces a rapid decrease in the highly sensitive primordial follicles of the 
ovarian reserve (A, C), resulting in a follicle-depleted ovary (B) and premature ovarian failure (POF). Depletion of the 
ovarian reserve disrupts normal endocrine function and the production of hormones such as follicle-stimulating hormone 
(FSH), luteinizing hormone (LH), estradiol, progesterone, inhibin B, and inhibin A (D), leading to hormonal imbalance 
similar to that seen in postmenopausal women. 
 
Reprinted with permission from J Gynecol Oncol. Kim SY, Kim SK, Lee JR, Woodruff TK. Toward precision medicine for 






The adverse effects of chemotherapy on ovarian function are well-recognized.   
During recent years, increasingly detailed data have become available on how different 
regimes may affect ovaries in short and long term (9-11). Although exact mechanisms 
behind gonadotoxicity are not yet fully understood (12), proposed hypotheses include (i) 
direct effect on the DNA of follicles inducing apoptosis, with dividing granulosa cells being 
particularly susceptible to damage; (ii) triggering a massive growth of dormant follicles, 
which are then destroyed; or (iii) inducing vascular damage and stromal fibrosis (11, 13-
15). Short-term effects, causing temporary amenorrhea, depend mainly on the apoptosis of 
growing follicles. Long-term effects are usually explained by damage to primordial 
follicular reserve (11).  
 
 
Figure 2. Proposed mechanisms for chemotherapy-induced damage on ovarian follicles. 
 
 
Reprinted from Hickman LC, Valentine LN, Falcone T. Preservation of gonadal function in women undergoing 
chemotherapy: a review of the potential role for gonadotropin-releasing hormone agonists. Am J Obstet Gynecol. 
2016;215(4):415-422, with permission from Elsevier. 
 
 
Chemotherapeutic drugs can be divided into five categories: alkylating agents, antitumor 
antibiotics, platinum-based drugs, antimetabolites, and taxanes (11). Growing data indicate 
specific toxicity of alkylating therapy on the patients’ reproductive function (16), with no 
consistent threshold for a safe dose existing at present. Classification of infertility risk 
induced by chemotherapy in females is presented in Table 1.  Nonetheless, individual risk 
is highly variable and difficult to predict, as the total impact of treatments depends on many 
different factors.  
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Table 1. Classification of infertility risk induced by chemotherapy protocols and 
radiotherapy in females. Adapted from (17). 
Chemo- or radiotherapy  
 
Degree of risk 
Hematopoietic stem cell transplantation and total body irradiation 
Radiotherapy to a field including the ovaries 
 
High risk >80% 
CAF, CMF, CEF x6 30–39 years of age ACx4 >40 years of age 
 
Intermediate risk 
ABVD, CHOP, CVP, AML, ALL CAF, CMF, CEF x6 <30 years of 

















Abbreviations: C, cyclophosphamide 600–1200 mg/m2; A, adriamycin 25–60 mg/m2; F, fluorouracil 600 
mg/m2; E, epirubicin 60 mg/m2; M, methotrexate 40 mg/m2; B, bleomycin 10 U/m2; V, vinblastine 6 
mg/m2; D, dacarbazine 375 mg/m2; V (O), vincristine 1.2 mg/m2–2 mg; P, prednisolone 40 mg/m2; H, 
hydroxydaunorubicin 50 mg/m2. 
 
 
In recent years, increasing knowledge about possible mechanisms involved in 
chemotherapy-induced ovarian damage has been applied to develop the therapies with 
potential to protect follicular reserve (18, 19). Further research in this field, parallel to the 
further spread of FP practice, will hopefully result in even better chances to preserve 




When the irradiation field includes the ovaries, radiotherapy may cause permanent ovarian 
damage.  Radiation therapy has a dose-related effect on primordial follicular reserve (20, 
21).  A dose of 2 Gray (Gy) represents the estimated dose required to destroy 50% of 
primordial follicles (22), confirming that oocytes are extremely sensitive to radiation. With 
increasing age, a gradual decrease in the non-growing follicle pool occurs, therefore a 
smaller dose of radiation may be sufficient to deplete the pool and to cause irreversible 
damage to the ovaries (23). 
 
In female patients, radiotherapy may also cause adverse effects on reproductive function by 
damage to the uterus, resulting in increased risk of preterm delivery (24) and stillbirth (25), 
or by damage to hypothalamus and pituitary, resulting in subsequent ovarian dysfunction 





Other antineoplastic therapies 
 
The effects of molecular targeted agents (such as monoclonal antibodies and kinase 
inhibitors) on female reproductive function are still largely unknown, though their use in 
treating different types of cancer is increasing (9).  
 
Surgical therapy involving reproductive organs may have obvious detrimental effects on 
future fertility.  
 
In women with hormone-positive BC, modern standards of treatment include adjuvant 
endocrine therapy for at least ten years. These adjuvant hormonal therapies (tamoxifen, 
aromatase inhibitors, GnRHa) have no direct irreversible effects on the ovarian function. 
However, an age-related reduction in the ability to conceive would inevitably  
occur due to the delay needed for completion of several years of endocrine treatment.  
 
2.1.2 Markers of post-treatment fertility 
 
Counseling young women on their risk of infertility after cancer treatments is a difficult 
task. Knowledge of the infertility rates after most current cancer treatments, and the impact 
of patients’ individual factors such as age, pretreatment fertility status, and genetic 
susceptibility to the treatments on the degree of fertility impairment is still limited.  
 
Damages to reproductive function in girls and young female cancer survivors result in 
hormone ovarian insufficiency, arrested puberty, premature ovarian insufficiency (POI), 
and infertility (23). According to the 2016 guidelines by the European Society of Human 
Reproduction and Embryology (ESHRE), POI can be defined as a clinical condition that 
develops in any adult female at an age younger than 40 years and is characterized by the 
absence of menstrual cycles for at least 4-5 months and two elevated serum follicle-
stimulation hormone levels in menopausal range (27).  
 
Persistence of regular menstruation after cancer treatment has been used to assess the 
residual ovarian function in many studies. In other words, amenorrhea has often been 
considered as a surrogate measure of infertility. Yet, maintenance or resumption of cyclic 
menses after treatment does not exclude compromised ovarian reserve and does not 
guarantee normal fertility (7). Thus, there is a need for accurate markers of ovarian function 
before and after treatment. Among those available today, the serum concentration of anti-
Müllerian hormone (AMH) and the antral follicle count (AFC) by transvaginal ultrasound 
are considered to be the most useful (28). Still, natural conceptions may occur in women 
with very low AMH/AFC, and the value of these biomarkers in the prediction of early 
menopause remains uncertain. Therefore, they have been proposed in a research context, 






2.1.3 Options to achieve motherhood after treatment of cancer 
 
Historically, female cancer survivors had to cope with infertility due to ovarian 
insufficiency developed as a sequela of their cancer treatment. Today, professionals 
involved in oncologic healthcare of girls and women of reproductive age are recommended 
to refer them for counseling on available fertility preserving options before gonadotoxic 
treatments are started. In selected cases of gynecological cancers diagnosed at an early 
stage (29, 30), fertility-sparing surgical treatments have been developed and implemented 
(31). International guidelines are being regularly updated (32-38). For women who present 
with childbearing wish after having developed ovarian failure, attempts to pregnancy with 
ART treatments using donor oocytes can be offered. Additional options to achieve 
parenthood for women with uterine factor infertility include uterus transplantation and 
surrogacy, the last one though not legally allowed in Sweden. Adoption remains an 
important alternative to parenthood for many cancer survivors. However, adoption agencies 
may have policies that do not encourage cancer survivors as prospective adoptive parents, 
due to considerations toward their medical history and associated risks for relapse. Thus, 
challenges of adoption processes have been reported in survivors of cancer (39).   
 
2.2 FERTILITY PRESERVATION METHODS 
 
The last two decades have brought several options for women with cancer considering FP. 
FP has emerged as a new clinical discipline, with the goal to develop methods to restore 
reproductive function in young cancer survivors. In Europe the terms “Fertility 
Preservation” or “Reproductive Oncology” have been preferred, whereas in the U.S, the 
term “Oncofertility”, coined by Dr. Woodruff in 2006, has become widely accepted. These 
terms refer all to a field of medicine that connects oncology with reproductive health, 
encompassing the endocrine health and fertility management options in the context of 
cancer disease (40).  
 
The first cryopreservation of embryos in a woman with BC was reported 1996. It was a 
result of a natural IVF-cycle prior to chemotherapy (41). A lot has happened since then. 
Today, cryopreservation of oocytes and/or embryos after controlled ovarian stimulation 
(COS) are considered to be the standard strategy for preserving female fertility when there 
is sufficient time (32), but cryopreservation of ovarian tissue has also been recently 
recognized as an established FP-method (42). Other strategies, such as pharmacological 




Figure 3. Fertility preservation strategies depending on the type of oncological treatment in 
females and males. 
 
Reprinted from Rodriguez-Wallberg KA, Oktay K. Fertility preservation during cancer treatment: clinical 
guidelines. Cancer Manag Res. 2014; 6:105-117. Originally published by and used with permission from Dove Medical 
Press Limited.  
 
2.2.1 Embryo and oocyte cryopreservation 
 
Embryo cryopreservation has been routinely used for storing surplus embryos after IVF for 
infertility treatment since the 1980’s, thus it has been an established method for FP during 
many years (44). Reassuring data on pregnancy and live birth rates with thawed embryos 
have been reported. Therefore, it has previously been offered as a first-choice FP method 
for women of reproductive age who have a partner and sufficient time for COS (7, 45).  
 
Cryopreservation of oocytes is another option for FP. It is particularly attractive for women 
without a partner and those not wishing to use donor sperms or to cryopreserve embryos 
due to religious, legal or ethical considerations. The newly developed technique of 
vitrification of oocytes has demonstrated a high efficacy, and an international consensus 
was reached in 2013 to recognize also oocyte cryopreservation as a clinically established 
method for FP (32). 
 
Both the aforementioned methods require about two weeks’ time for controlled ovarian 
stimulation (COS) with gonadotropins, to finally inducing oocyte maturation of large 
follicles with a hCG or GnRHa trigger. These treatments are monitored using transvaginal 
ultrasound and blood tests for hormonal determinations. After collection of the oocytes 
through ultrasound-guided transvaginal needle aspiration, these are cryopreserved, 
Oncologic surgery
Fertility-sparing surgery preserving gonads. 
Preservation of the uterus in females. Use of 
cryopreservation may also be considered prior to 
surgery if the risk of gonadal damage is high
Radiation therapy 
to pelvic organs 
and gonads
Shielding aiming at reducing damage of reproductive 
organs and surgical ovarian transposition




high risk of 
gonadal damage
Use of cryopreservation methods such as sperm 
banking for males, freezing of embryos and oocytes





Cryopreservation may be considered in women >33 
years of age when being planned for a 5-year tamoxifen
treatment and >28 years if a 10-year treatment is 
planned, as natural fertility diminishes with age.
If the treatment includes: The following options should be considered:
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currently by vitrification methods (46). Only mature oocytes are usually cryopreserved and 
immature oocytes are discarded. However, in vitro maturation methods have been proposed 
to increase the yields (47). If the oocytes are fertilized in vitro the resulting embryos can be 
cryopreserved at cleavage stage (day 2-3) or at blastocyst stage (day 5-6). For women with 
breast cancer, there is usually a gap of 4-6 weeks between surgery and the start of 
chemotherapy, and therefore sufficient time is available to undergo ovarian stimulation 
(48), which requires about two weeks to complete. Oocyte collection can also be performed 
without ovarian stimulation (“natural-cycle IVF”), aiming at obtaining the single oocyte 
that naturally would ovulate (49). 
 
2.2.2 Ovarian tissue cryopreservation 
 
Ovarian tissue cryopreservation does not require any hormonal stimulation, sperm donor or 
sexual maturation, and it is therefore a unique FP option for young girls with cancer, or for 
those patients who need to start chemo- or radiotherapy promptly. This method has been 
considered experimental for many years (32, 35, 50) until recently, when recognized as an 
established FP-technique by the American Society of Reproductive Medicine (42). Ovarian 
tissue is usually harvested laparoscopically and frozen to be later thawed and re-implanted. 
The best site for transplantation seems to be the orthotopic position, but subcutaneous areas 
such as forearm or lower abdomen have been described (51). 
 
The first ovarian transplant procedure was reported in 2000 (52). Since then, re-
implantation of ovarian tissue has resulted in 87 live births in 69 women, and a total of 93 
children born (53). Taking into account not only peer-reviewed publications but also 
abstracts and congress proceedings, a recent review reported a total of 130 children born 
(54). In a meta-analysis from 2017, cumulative live birth and ongoing pregnancy rate per 
patient worldwide was evaluated to be 37% (55). However, according to newer data, with 
increased experience and improved surgical techniques, current success rates are likely to 
be even higher (56). By combining vitrification of oocytes and cryopreservation of ovarian 
tissue, a theoretical live birth rate of 50-60% was proposed to be possible. Therefore, this 
combined technique is suggested for young women who are at high risk for POI, when 
enough time for this is available (54).  
 
Concerns that re-implantation of ovarian tissue in women previously treated for cancer may 
re-introduce cancer cells have been raised (57), and screening of ovarian tissue for 
malignant cells should always be performed when this FP method is used. In vitro 
maturation and cryopreservation of oocytes from harvested ovarian tissue could open new 
possibilities for the patients with high risk of ovarian involvement. Another potential to 
utilize cryopreserved ovarian tissue involves the development of so-called transplantable 
artificial ovary; with primordial follicles being isolated and transferred onto a scaffold, 
eliminating the risk of re-introducing malignant cells (58, 59). Today, both these techniques 




Figure 4. Options for fertility preservation in females. 
 
 
If the patient is prepubertal or requires immediate chemotherapy (Panel A), ovarian tissue is removed in the form of 
multiple biopsy specimens (or an entire organ) and cut into cortical strips. The tissue is then cryopreserved by slow 
freezing on site (or transported to a processing site at a temperature of 4°C). After thawing, if there is no risk of 
transmitting malignant cells, the ovarian tissue can be grafted to the ovarian medulla (if at least one ovary is still present) 
or re-implanted inside a specially created peritoneal window. If there is a risk of transmitting malignant cells, ovarian 
follicles can be isolated and grown in vitro to obtain mature oocytes, which can then be fertilized and transferred to the 
uterine cavity. Isolated follicles may be placed inside a scaffold (alginate or fibrin), creating an artificial ovary that can be 
grafted to the ovarian medulla or peritoneal window. If the patient is post-pubertal and chemotherapy can be delayed for 
approximately 2 weeks (Panel B), mature oocytes can be removed after ovarian stimulation and vitrified on site. After 
thawing, they can be inseminated and transferred to the uterine cavity in the form of embryos. This technique can also be 
used in women with benign diseases or in those with age-related fertility decline. The techniques in Panels A and B can 
also be combined, with ovarian-tissue cryopreservation followed by controlled ovarian stimulation and vitrification of 
oocytes. The combined technique theoretically yields a 50 to 60% chance of a live birth. 
 
Reproduced with permission from Donnez J, Dolmans MM. Fertility Preservation in Women. N Engl J Med. 
2017;377(17):1657-1665. Copyright Massachusetts Medical Society. 
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2.2.3 Other options for fertility preservation 
 
Other FP options include ovarian suppression and ovarian transposition.  
 
Ovarian suppression through gonadotropin-releasing hormone analogues (GnRHa) is 
theoretically an attractive approach, as pharmacological prevention of ovarian depletion 
could be a better choice than invasive FP methods. Until now, there is still controversy 
regarding the efficacy of this method (60), and the latest guidelines on FP provided by the 
American Society of Clinical Oncology, ASCO, recommend to use it only when proven FP 
methods are not feasible (35). The relevant issue is that although randomized trials have 
been conducted, fertility has not been their primary outcome (61). Additionally, none of the 
trials has been blinded, thus the groups of women that received GnRHa in the studies have 
attempted pregnancy more frequently that the women in the control groups (62). Studies 
with improved design are needed, and if proven to be safe and effective, GnRHa can be a 
good alternative in patients interested in reducing the risk of infertility, additionally to post-
treatment amenorrhea and menopausal symptoms (63).  
 
Ovarian transposition means that the ovaries are surgically moved away from the radiation 
field and it can be practiced when pelvic radiation is a part of the antineoplastic treatment. 
This technique was first described in 1958 (64), but its effectiveness is still debated. In a 
systematic review from 2019, including 765 patients with ovarian transposition, the return 
of ovarian function was found in 20-100% of women receiving external beam radiation to 
the pelvis, in 64-100% of those receiving pelvic brachytherapy alone, and in 0-69% of 
those who also received concurrent chemotherapy (65).  
 
Trachelectomy (removal of the cervix, upper vagina and parametrium instead of removal of 
the whole uterus), as well as other conservative surgical and radiation therapy approaches 
to specific pelvic cancers, are also available but they lay outside the scope of this review.  
 
2.3 BREAST CANCER AND FERTILITY 
 
Breast cancer (BC) is the most common malignancy affecting women during their 
reproductive years (66). About 15% of all invasive BC cases occur in women of 
reproductive age, with clustering between the ages of 30 and 40 years (66, 67). Early 
diagnosis and improved treatment options have remarkably improved survival rates over 
the last few decades: the 5-year relative survival in women diagnosed with BC prior to age 
of 45 has been estimated to 88% (2). In general, the predicted 5-year relative survival for 
patients with BC is now close to 90% (68).  
 
There are four main subtypes of female BC (1):  
 HR+/HER2- ("Luminal A") 
 HR-/HER2- ("Triple Negative") 
 HR+/HER2+ ("Luminal B") 
 HR-/HER2+ ("HER2-enriched") 
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HR stands for hormone receptor. HR + tumor cells have receptors for the hormones 
estrogen or progesterone so that these hormones can promote the growth of HR+ tumors. 
HER2+ means that tumor cells produce high levels of a protein called HER 2 (human 
epidermal growth factor), which is associated with the development and progression of 
certain aggressive forms of BC.  
 
Treatment options and survival prognosis differ between the subtypes of BC. HR+/Her2- 
subtype has been reported to have the best survival pattern, followed by the HR+/Her2+ 






















In women below age of 40 years, BC often presents with biologically aggressive features, 
thus chemotherapy in combination with other treatments is a standard of care. Possible 
ovarian effects of chemotherapy have been described in this thesis. Approximately 5% of 
women with BC diagnosed at age 30, 32% diagnosed at age 35, and 80% diagnosed at age 
40, experience post-treatment infertility despite return of their menses (69). Alkylating 
agents (e.g., cyclophosphamide) are particularly harmful depleting the follicle pool, and the 
gonadal toxicity is also dose-related and age-dependent, thus the damage is more evident in 
patients of older age with an already reduced follicle pool in their ovaries (32). A review by 
Oktay et al. reports that about 20-80% of survivors older and less than 20% of survivors 
younger than age 40 would experience ovarian failure after four cycles of doxorubicin plus 
cyclophosphamide (AC) (70). In xenograft models, apoptotic death of primordial follicles 
was shown to be the main mechanism of ovarian damage induced by AC and doxorubicin 
(71).  AC followed by docetaxel was reported to result in the highest rate of amenorrhea 12 
months after treatment (70%), followed by concurrent docetaxel plus AC (58%), and 
doxorubicin plus docetaxel (38%) (72). Adding the monoclonal antibody trastuzumab to the 
standard chemotherapy does not seem to have any further effect on the risk of treatment-
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Figure 5. Subtypes of breast cancer in women and 5-year relative survival  
 






During the standard whole-breast radiotherapy (50 Gy), the dose that reaches the pelvis 
via internal scatter is about 2.1-7.6 centigray (Gy x 10−2), which is unlikely to have any 
negative effects on the function of uterus and ovaries (74). Although radiation to the 
pelvis is low, pregnancy and oocyte harvest are not recommended during radiotherapy for 




While chemotherapy is often directly toxic for ovaries by destroying the ovarian follicles, 
endocrine treatments such as tamoxifen have also indirect effects on fertility in women of 
pre-menopausal age. Endocrine therapy per se can result in impaired ovulatory and 
endometrial function, including temporary amenorrhea (75). While on treatment with 
tamoxifen, pregnancy is contraindicated because of the increased risk of teratogenicity (75, 
76). The treatment with tamoxifen is currently indicated for five to ten years in women with 
estrogen receptor (ER) positive BC, depending of the specific risk evaluation. Thus, there is 
an overall consequence of developing age-related infertility in women who need to 
complete their endocrine therapy prior to attempting pregnancy, as natural fertility declines 
with age. The standard chemotherapy regime for BC is assumed to result in approximately 
10 years’ worth of ovarian reserve loss (48). When there is a need for both chemotherapy 
and endocrine BC treatment in a woman of premenopausal age, the risk of subsequent 
infertility should be considered as very high (77).  
 
2.3.2 Wish and chance of pregnancy after breast cancer 
 
At the time of cancer diagnosis, approximately half of young BC patients wish to become 
pregnant after completing therapy (33). Some evidence suggests that women with BC may 
prefer a less toxic regimen of chemotherapy to avoid gonadal toxicity and risk of infertility 
if given a choice, even if this treatment is slightly inferior in terms of protection from 
recurrence (34). However, BC survivors have the lowest subsequent pregnancy rate among 
female cancer survivors, which is approximately 70% lower than expected in the general 
population (35, 36). This difference can be explained by the gonadal toxicity of 
chemotherapy, longer periods of endocrine therapy in patients with the hormone-sensitive 
disease, and also a concern that pregnancy could cause cancer relapse (27). There is 
growing evidence that the latter fear is not justified (78). In the most recent treatment 
period, the correlation between history of BC and subsequent reduced pregnancy rate 
appears to be less pronounced than in the former years, probably reflecting not only a 
change in treatments but also in how patients are advised by their health-care providers 
regarding post-cancer pregnancy (35). 
 
Since young women with BC report great distress about the prospect of infertility (5), it is 
of utmost importance to address this concern and inform patients that FP can improve their 
chances of becoming pregnant after treatment.  
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2.4 FERILITY PRESERVATION IN WOMEN WITH BREAST CANCER 
2.4.1 Safety 
 
To date, studies have not shown any increased risk of BC recurrence after FP procedures, 
but the follow-up time in the most studies has been relatively short (79-81).  
 
Cryopreservation of embryos and oocytes are the most widely used FP methods in women 
with BC; both these methods require COS. During ovarian stimulation, peak estradiol 
levels may increase several-fold compared to physiological peri-ovulatory levels (82, 83). 
Research has shown that estrogen and its metabolites may play a role in the propagation of 
breast cancer (84). Although the studies have so far not shown that short-term exposure to 
exogeneous estrogen may worsen prognosis in women with BC (81, 85), there has been a 
concern that hormonal stimulation may be potentially dangerous for women with ER-
positive BC. Tamoxifen and letrozole as long-term adjuvant therapy improve prognosis for 
women with ER-positive BC (86). Based on this fact, potentially safer protocols for ovarian 
stimulation with the addition of these agents have been developed in recent years (87, 88). 
Addition of letrozole has been reported to have higher efficacy than tamoxifen, therefore 
the former is usually preferred (89). Additional improvements aiming at higher safety of the 
stimulation protocols using letrozol in women with BC include a maturation trigger using 
GnRHa (90). 
 
In a matched cohort study including 148 women with BC, Rodriguez-Wallberg et al. 
reported that hormonal stimulation, with or without letrozole, was not associated with an 
increased risk of BC recurrence during a mean follow-up time of 6.6 years, when compared 
to age-matched unexposed controls (81). These findings support the practice of FP in 
women with BC, irrespective of the need of hormonal stimulation. Still, the question about 
the potential benefits of letrozole on the reproductive outcome and long-term safety 
remains open.   
 
In women diagnosed with BC, the time window between surgery and start of chemotherapy 
usually provides a sufficient period for ovarian stimulation. Therefore, in the studies 
mentioned above, tumors were generally removed before the start of COS for FP. Data 
concerning safety of COS for FP prior to neoadjuvant therapy and/or surgery (i.e. without 
previous tumor surgery) are scarce (91, 92).  
 
When neoadjuvant chemotherapy is indicated with prompt start, or in cases where ovarian 
stimulation is not desired, cryopreservation of ovarian tissue can be offered instead. This 
method eliminates potential risks of hormonal stimulation but the chance of future 
pregnancy relies on the functionality of the tissue regained after re-transplantation.  Certain 
concern of reintroducing malignant cells with re-implantation of ovarian tissue has been 
articulated. However, to date, studies have not shown any evidence of malignant cells in 




2.4.2 GnRH antagonist protocols - which one to choose? 
 
A Cochrane review from 2013, summarizing evidence regarding safety and efficacy of 
tamoxifen and letrozole addition to standard stimulation protocols in women with ER-
positive BC, did not find any randomized controlled trials to refer to (94). Investigating 
possible impact of co-administration of letrozole on the oocyte yields, two studies reported 
no difference (87, 95), while two others found small but significant decrease in oocyte 
yields (96, 97).   
 
A multicenter randomized open-label trial was started in the Netherlands and Belgium in 
2014 with the aim to evaluate the effectiveness of ovarian stimulation with tamoxifen and 
letrozole compared to standard ovarian stimulation on the number of oocytes retrieved (98). 
The study planned to enroll 53 women in each group (letrozole vs tamoxifen vs standard 
ovarian stimulation), and it is ongoing. Hopefully, the results of this study will contribute to 
the understanding of the effect of different types of ovarian stimulation in women with BC. 
It would also pave the way for long term follow-up on the safety of this procedure. 
 
The use of GnRHa instead of standard hCG for ovulation trigger is reported to reduce the 
risk of ovarian hyperstimulation. In women with BC, studies comparing the use of GnRH 
agonist vs hCG trigger in COS with co-administration of letrozole have found no difference 
in the total number of retrieved oocytes, but a higher proportion of mature oocytes with 
GnRH agonist (90, 99). 
 
A more recent improvement has been the introduction of random-start stimulation protocols 
enabling cancer patients to undergo COS for yielding of oocytes irrespective of the phase of 
their menstrual cycle (100). A systematic review on the utility of random-start ovarian 
stimulation for FP was published 2017(101). It suggested that random start could shorten 
interval between ovarian stimulation and oocyte retrieval, with a yield of mature oocytes 
and embryos that was comparable to that of conventional stimulation protocols, albeit with 
a higher gonadotropin dose required in the former.  
 
Most available studies on the efficacy and safety of these new approaches in the population 




The short-term efficacy of FP can be measured as the number of oocytes or/and embryos 
cryopreserved, with respect to different COS protocols, in a specific patient population that 
determines the indication of FP.  Long-term efficacy can be measured as pregnancy and 
live births rates post-diagnosis, with specific focus on pregnancies and live births achieved 
using cryopreserved specimens.  
 
So far, data on utilization rate of oocytes and embryos and the rate of subsequent 




Regarding the outcomes of embryo cryopreservation in BC patients, Oktay et al have 
reported pregnancy rates comparable to those expected for IVF in general population (41). 
Summarizing outcomes of currently used FP procedures for oncological indications in a 
literature review from 2019, ter Welle-Butalid et al. report that 23% (range 13-63%) of 614 
women underwent one or more embryo transfer, and 40% of those (range 9-75%) had a live 
birth (59). The proportion of patients returning for embryo transfer after prior oocyte 
preservation varied from 0 to 5%, and the live birth rate among those who returned was 
between 33 and 50%.  BC-specific results were not reported. In a retrospective study of 
Cobo et al., the cumulative live birth rate (CLBR) after oocyte cryopreservation in 1073 
women with cancer (whereof 64.4% had BC) was compared to that in 5289 healthy women 
with elective oocyte banking (15). Altogether, 80 cancer survivors attempted pregnancy 
after treatment, resulting in a CLBR of 35.2%. Age over 35 years and/or oncological 
indication for oocyte vitrification were found to negatively impact pregnancy and live birth 
rates in that study (15).  
 
In 2018, Moravek et al. compared long-term outcomes of cancer patients who pursued FP 
(n=204) and those who did not (n=293), with a live birth rate of 6.4 % vs 5.5% after 
spontaneous pregnancies (17). Twenty-one women returned to use cryopreserved 
specimens, resulting in 16 live births. Of 497 women included in that study, 52.7% had BC. 
Further, in a recently published cross-sectional study of Vriens et al., a cohort of 118 
women with early-stage BC received FP counseling and 34 of them chose FP (18). The 5-
year live birth rate was 27% in total; 10 women in FP group gave birth to 12 babies, and 16 
women in non-FP group gave birth to 20 babies, with a high rate of spontaneous 
pregnancies. Only 3 women applied for the transfer of their cryopreserved embryos, two of 
them also asked for pre-implantation genetic diagnosis of the frozen embryos because they 
were carriers of a BRCA1-mutation. 
 
Most of the aforementioned studies have been published within the last 3 years. Data on the 
efficacy of FP at the start of this project were even scarcer. As the reports on long term 
reproductive outcomes after FP with oncological indications are mostly of retrospective 
character, with relatively small numbers of patients included, there is still an obvious need 
to conduct prospective studies of large scale.  
 
2.5 PREGNANCY AFTER CANCER 
2.5.1 Pregnancy rates 
 
In general, the pregnancy rate in cancer survivors is expected to be lower than that of the 
general population, with female patients being more severely affected than male (106-109).  
 
Several large studies have been published providing invaluable information related to the 
likelihood of pregnancy and live birth in survivors of childhood cancers, in relation to both 
diagnoses and treatments (109-113). Meanwhile, data on survivors of cancer in adulthood 
and BC in particular are limited. A pooled pregnancy rate of 3% has been estimated from 
population-based studies on women who had received treatment for BC (altogether 711 
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women included, median age 31-33 years) (114). In a large cohort study by Nichols et al, 
the 10-year cumulative incidence of postdiagnosis live birth in women with BC was 8% 
(4,445 women included), while it was 30% and 29% from melanoma and Hodgkin 
lymphoma, respectively (115). 
 
In a Norwegian register-based study, female cancer survivors had a 39% lower pregnancy 
rate than the general population during a median observation time of 6 years. This 
observation was highly dependent on the cancer type, with survivors of melanoma or 
thyroid cancer having pregnancy rates highly comparable with the general population, 
while BC survivors had the lowest rates of post-cancer motherhood (108). To further study 
the true pregnancy deficit in the population of female cancer survivors, Anderson et. al 
recently conducted a large cohort study based on data from the Scottish Cancer register 
(116). They concluded that cancer survivors achieved fewer pregnancies across all cancer 
types (overall reduction of 38%), with marked reduction in women with breast, cervical and 
brain/central nervous system tumors, and leukemia. The history of treatment with 
chemotherapy and radiotherapy were both shown to contribute to the reduction, 
highlighting the importance of appropriate fertility counseling at the time of diagnosis.  
Overall for different cancer forms, higher rates of pregnancies have been reported with 
more recent treatment period (112, 116), possibly reflecting an increase in risk-adapted use 
of gonadotoxic treatment methods, higher rates of FP, and a change over time in how the 
patients are advised regarding post-cancer pregnancy.    
 
Even though research has shown an increased risk of emotional distress due to iatrogenic 
infertility (117, 118), it is important to keep in mind that pregnancy rate in the population of 
cancer survivors reflects far more than only fertility or infertility rate. Other factors than 
gonadotoxic effects of antineoplastic treatments can affect pregnancy rates among cancer 
survivors. Partnership, desire for having children, potential concerns about how the 
pregnancy may affect the patient’s own health and prognosis, or fear of recurrence during 
the eventual offspring’s childhood, are all relevant variables that may influence the decision 
to become or not to become pregnant.   
 
2.5.2 Safety of pregnancy after cancer 
 
Regarding the safety of pregnancy following cancer, there are no apparent reservations. 
Still, concerns have been articulated when it comes to safety of pregnancy after BC and 
ER-positive BC in particular, as pregnancy could provide potentially detrimental endocrine 
stimulation of residual cancer cells (119, 120). So far, results of studies on the impact of 
subsequent pregnancy on long-term BC outcomes have been reassuring, also in women 
with ER-positive disease (121-127). In this context, selection bias, known as the “healthy 
mother effect”, has often been discussed. Valachis et al. performed a meta-analysis of 
published articles that have tried to overcome the “healthy mother effect” bias.  The results 
of that study indicate that in early breast cancer patients, pregnancy that occurs at least 10 
months after diagnosis does not jeopardize prognosis and may actually confer significant 
survival benefit (126). Similarly, in a meta-analysis by Hartman et al., a subanalysis 
controlling for “healthy mother effect” included only studies that have been controlled for 
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the aforementioned bias by matching for nodal status, ER status, disease-free interval and 
treatment details. A total of 17 049 women were included in the subanalysis. Reduced risk 
of death, pHR 0.65 (95%CI 0.52-0.81), was observed in women who became pregnant after 
treatment of BC, as compared to women who did not become pregnant (128). 
 
In clinical practice, the timing of subsequent pregnancy is a challenge. Most experts find it 
reasonable to postpone pregnancy for 2 years following diagnosis, mainly to overcome the 
period associated with a relatively high risk of recurrence (33). Lambertini et al. reported in 
2018 that in a cohort of 333 women with pregnancy after BC and 874 matched nonpregnant 
controls, no difference in disease-free survival was observed after a median follow-up of 
7.2 years; time to pregnancy had no impact on patients’ outcomes (124). In a cohort of 
Taiwanese women (249 exposed matched to 4 unexposed controls), Chuang et al. reported 
lower mortality in women who became pregnant after BC diagnosis, with a more 
pronounced association for those who became pregnant more than 3 years after diagnosis 
(121). Today, most clinicians adopt an individualized approach, taking into consideration 
such parameters as risk of recurrence, given treatment and patients fertility status. For 
women with ER-positive BC, the need of 5-10 years of endocrine therapy may make the 
situation particularly complicated. Temporary interruption of endocrine therapy to allow 
pregnancy has been proposed (129). The ongoing POSITIVE study (NCT02308085) aims 
to evaluate the safety of this approach in women who have received 18 to 30 months of 
endocrine therapy (129). 
 
2.5.3 Pregnancy outcomes 
 
The rate of spontaneous pregnancy loss in cancer survivors is comparable to siblings and 
the general population (130, 131). The only exception with higher rates is the group of 
women with the history of cranial or abdominopelvic radiation, who are also more 
frequently affected by second-trimester losses (110, 130).  
 
Higher rates of preterm birth have been reported in cancer survivors (1.5 to 2-fold 
compared to the general population or siblings); the elevation of risk was related to 
abdominopelvic radiation in a dose-dependent fashion (24, 132). The risk to have a low-
birth-weight baby (<2500 g) has also been observed to be higher among female cancer 
survivors compared to controls. However, higher rates of small for gestational age offspring 
were only observed in women with a history of abdominopelvic radiation (24, 132). This 
suggests that preterm birth rather than intrauterine growth restriction lies behind those 
elevated rates of low-birth-weight babies among female cancer survivors.  
 
Regarding other potential pregnancy-related complications, an increased risk of gestation 
diabetes (RR 2.62, 95% CI 2.22-3.04), pre-eclampsia (1.32, 1.04-1.87), post-partum 
hemorrhage (2.83, 1.92-4.67), cesarean delivery (2.62, 2.22-3.04), and maternal postpartum 
hospitalization >5 days (3.01, 1.72-5.58) in survivors of adolescent and young adult cancer 
survivors in comparison to females with no cancer history has been reported in a large 
population-based study (133). These data emphasize the importance of adapted pre-
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conceptional counseling and adapted pregnancy surveillance in female cancer survivors, 
with involvement of both obstetric and oncologic expertise.  
 
Health risks in the offspring of female cancer survivors have been studied relatively 
extensively during recent years, and the results are reassuring. No significantly increased 
risks of congenital malformations (134, 135), chromosomal abnormalities (136), or cancer 
(except for rare events of familial cancer syndrome) (137) have been reported.  
 
2.6 PREGNANCY WITH DONOR OOCYTES IN FEMALE CANCER SURVIVORS  
 
For women who develop iatrogenic ovarian failure, fertility treatment with donor oocytes 
may provide a valid option to experience pregnancy and biological parenthood. 
 
In 2016, Luke et al reported in a population-based cohort study that the likelihood of a live 
birth after ART was reduced among female cancer survivors when using autologous 
oocytes, while it was similar to women without cancer when donor oocytes were used 
(138). These results are encouraging, although the previously mentioned concerns 
regarding potential pregnancy risks related to cancer treatments’ adverse effects remain.  
 
Current evidence suggests that oocyte donor treatment in itself is a significant and 
independent risk factor for pregnancy complications (139-141). Some studies indicate a 2 to 
3-fold increased risk of gestational hypertension and preeclampsia (PE) (142-144), a higher 
incidence of gestational diabetes (144), preterm delivery (145), placental abnormalities 
(145) and first trimester bleeding (143, 144, 146). Oocyte donation is often associated with 
advanced maternal age, which is itself a known risk factor of adverse obstetric and perinatal 
outcomes. However, even in women of younger age, increased pregnancy complications 
such as hypertension have been reported in pregnancies using donor oocytes (147).  
 
In Sweden, ART using donor oocytes became approved in 2003. These treatments have been 
exclusively provided by university hospitals that cover large healthcare regions. The costs 
are financed by the tax-funded healthcare system available to the whole population. 
Treatments with donor oocytes require thorough physical and psychosocial screening of the 
oocyte recipient candidates, and they are restricted to women 25-40 years of age who are 
healthy at the time of attempting pregnancy. A strict policy of single embryo transfer is also 
practiced in Sweden to reduce additional pregnancy risks of multiple births (148, 149).  
 
There is a particular lack of data on obstetric and perinatal outcomes of pregnancies 
achieved using donor oocytes in women previously treated for cancer. Swedish strict 
policies regulating treatments with donor oocytes minimize potential differences in health 
status between women with and without a history of cancer undergoing these treatments, 
providing a possibility to study the true effects of cancer history on obstetric and perinatal 




3 AIMS OF THE THESIS 
 
The overall aim of this thesis has been to explore the efficacy and safety of different 
methods for fertility preservation and fertility treatment in young women with cancer. Its 
main focus has been on women with breast cancer (BC) as this is the most common 
malignancy affecting women of reproductive age. 
 
Specific aims:  
 
Study I: To investigate whether there is a higher risk of obstetric and 
perinatal complications after treatment with donor oocytes in 
women with cancer history compared to women without prior 
cancer.  
 
Study II: To explore the trends over time in women's decisions after 
standardized fertility preservation counseling.  
 
To evaluate the efficacy of the FP methods by assessing the 
return rates and utilization rates of cryopreserved specimens after 
long‐term follow up. 
 
Study III: To investigate the efficacy and safety of current approaches to 
controlled ovarian stimulation aimed at fertility preservation in 
women with breast cancer.  
 
Study IV: To compare and evaluate long-term reproductive outcomes after 




4 MATERIALS AND METHODS 
4.1 EPIDEMIOLOGICAL STUDY DESIGN AND ANALYSIS 
 
Designs used for quantitative research can be broadly categorized into two groups: 
analytical and descriptive. The goal of any analytical study is to test a hypothesis, to find a 
possible association/causality between exposure and outcome. Analytical studies may be 
further divided into experimental and observational. In experimental studies, the researcher, 
in one way or another, affects the exposure. Observational studies, on the other hand, do not 
involve any form of practical experiment: the researcher collects the data, but does not 
manipulate the exposure. Observational studies can be descriptive and/or analytical. 
 
Table 2. The most common types of epidemiological study design 
 Experimental Observational 
Descriptive  Case report, case report series, incidence study 
Analytical 
Randomized Clinical Trials 
Interventional studies 
Cohort studies, case-control studies 
 
For assessing medical evidence, different hierarchies have been proposed over time (150), 
where the studies are graded according to their ability to accurately represent “the truth”, 
mainly dependent on their design and quality. RCTs (Randomized Clinical Trials) and 
meta-analyses of RCTs are considered the most reliable evidence. Due to the nature of 
randomization, they are able to control for potential bias by creating an equal distribution of 
prognostic variables (both known and unknown) within a sample population (151).  
 
However, randomized studies are not feasible in certain scenarios, or may be simply 
unethical. Thus, observational studies are sometimes the only option to acquire valuable 
data on specific scientific questions. Although observational studies generally cannot prove 
causality, they provide tools for estimating associations between variables and risks of 
outcomes occurring. Studies in this thesis utilize observational epidemiological design. 
More precisely, all of them are cohort studies. Some of the basic characteristics of this 




The study population in a cohort study is identified based on exposure, so that the groups of 
individuals included are similar in many ways but differ by a certain characteristic 
(exposure). Both groups (exposed and unexposed) are followed over time, and the 
outcome(s) are recorded continuously.  
 
The advantages of a cohort study include the opportunity to study associations between 
multiple outcomes and multiple exposures. When randomization to a certain exposure is not 
possible due to ethical or practical reasons, the cohort design is a useful alternative. In 
addition, inclusion of large study samples, for instance, through the use of national 
registers, makes it possible to study rare exposures. Compared to RCTs, cohort studies are 
usually less expensive to conduct, and may allow longer follow-up time. The disadvantage 
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is that the studies with this design may suffer from confounding by indication and selection 
bias. If the groups are not truly comparable at the baseline, differences in the outcome may 
reflect other factors rather than a measure of the association to the study exposure. 
 
Cohort studies can be prospective or retrospective, typically depending on the time of the 
occurrence of the outcome in relation to the time at which the study was initiated.  
 
In prospective studies, the cohort is followed forward in time, and specific outcomes and 
other related variables are documented. At the time when subjects are enrolled, baseline 
exposure information is collected, but the important thing is that none of the subjects have 
yet developed any outcome of interest. The variable of interest is measured in advance of 
the outcome of interest (152).  
 
Retrospective design, on the other hand, means looking at historical data. The sample and 
the outcome are defined, and then the researcher looks back in time to collect data about 
factors believed to be related to already existing outcome, for instance, by sending 
questionnaires to the study participants (152).  
 
While retrospective studies may provide opportunity to acquire data from existing sources 
(such as hospital notes), being less costly and more quickly implemented than prospective 
designs, that usually require time and funding for follow-up, they may be limited by 
accuracy and comprehensiveness of previously recorded data such as recall bias in the case 
of self-reported information (153). 
 
As previously mentioned, cohort studies can be used to investigate possible association 
between variables, but generally not for establishing causation. Still, by measuring the 
strength of associations and the consistency of associations across a range of studies, 
inferences about causation can be drawn.   
 
Different measures of association and statistical methods to estimate them 
 
Different measures of estimating the strength of the association between exposure and 
outcome are used in different settings. A brief description of such measures and the relevant 
statistical methods for their estimation used in the studies of this thesis follows below.  
 
The probability of the occurrence of an event, or the risk of an event, can be calculated by 
dividing the number of events by the number of people at risk. The risk ratio (RR), often 
referred to as relative risk, is the risk among exposed subjects divided by the risk among 
unexposed subjects. Similarly, the odds of an event can be calculated by dividing the 
number of times an event happened by the number of times it did not happen within the 
same population. The odds ratio (OR) is the odds among the exposed divided by the odds 
among the unexposed. The OR is a close approximation of the risk ratio when the outcome 
is rare. A rate is defined as the number of times that an event happens in a population over 
a fixed period of time. The rate takes person-time into account, which is important when the 
risk changes over time or when the follow up time differs between exposed and unexposed 
subjects. The hazard rate is the instantaneous hazard of an outcome event. It is calculated 
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as number of events divided by the person-time at risk. The hazard ratio (HR) is the ratio of 
the hazard rate in the exposed group divided by the hazard rate in the unexposed group. 
HRs can be interpreted differently depending on the outcome of interest, for instance, as an 
incidence rate ratio when estimating differences in incidence rates, or as a mortality rate 
ratio when studying mortality. 
 
Regression modeling is one of the most important statistical methods used in analytical 
epidemiology. Regression models are often applied to investigate the association between 
an exposure and an outcome, while allowing for adjustment for other factors that may 
influence both the exposure and the outcome called confounders. Regression models can be 
used for exposures and confounders on any measurement scale, i.e. binary, continuous, or 
categorical. Depending on the measurement scale of the outcome and the study's design, 
different regression models can be used (154). Linear regression is suitable for continuous 
outcomes and can be used to estimate the mean difference in outcome between exposed and 
unexposed individuals or the expected change in the outcome for a one-unit change in a 
continuous exposure. The fundamental assumption of linear regression models is that the 
association between exposure and outcome is linear. Logistic regression is used to estimate 
ORs for binary outcomes (155). Cox proportional hazards regression is commonly used for 
survival analysis to analyze time-to-event data. Cox regression estimates HRs for binary 
outcomes without making any assumptions about the underlying hazard rates of the 
exposed and unexposed individuals (154).  
 
4.2 ERRORS IN EPIDEMIOLOGICAL RESEARCH 
 
Epidemiological studies measure characteristics of populations; they measure the frequency 
of an outcome or aim to investigate associations between exposure and outcome. Since 
these studies are being carried out by human beings on human beings, they have both 
practical and ethical constraints, and are almost invariably subjected to errors. To achieve 
accurate estimates of possible associations, both the risk of systematic and random errors 
needs to be addressed.  
 
4.2.1 Systematic error 
 
Systemic error can be understood as any difference between the true value and the value 
obtained in the study that cannot be explained by random error, i.e. any systematic tendency 
to under- or overestimate an association because of deficient design or execution. 
Systematic error may negatively affect the validity of the study, both internal (how well the 
study is conducted) and external (generalizability of the findings). Confounding, selection 
bias and information bias are often considered to be the main sources of systematic error.  
 
Since the exposure is not randomly assigned in observational studies, the subjects in the 
exposed and unexposed group may differ systematically due to other reason than exposure. 
When exposure and outcome share common cause(s), a spurious association termed 
confounding will be induced between them. Age and gender may act as confounding factors 
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in many studies but in general, confounding is unique for each studied association, and 
requires detailed knowledge of the respective scientific field.  
 
There are methods for preventing confounding at the design level (e.g., matching and 
restriction) and at the analysis stage (e.g., stratified analysis or statistical regression 
models). Distortion that remains after controlling for all known confounders in the design 
and/or analysis is known as residual confounding. Thus, awareness of the risk for 
confounding is important at all stages of conducting a study, and conclusions should not 
only be based on results of statistical analyses and characteristics of the study design, but 
should incorporate the existing knowledge about the studied phenomena.  
 
Selection bias is another source of systematic error. It occurs when there is a systematic 
difference between those who are enrolled in the study and those who are not (affecting 
generalizability), or those exposed and those who are not (affecting comparability between 
the groups). As the association between exposure and outcome among those who do not 
participate in the study is usually unknown, eventual selection bias can in most cases only 
be inferred rather than observed.  
 
Thirdly, information bias results from systematic differences in classifying subjects 
regarding their exposure and outcome status. For continuous variables, information bias is 
referred to as measurement error, while for categorical values it is called misclassification, 
and it can be further divided in non-differential and differential misclassification. 
According to Rothman (156), these two types of misclassification can be defined as 
follows:  
 
"For exposure misclassification, the misclassification is nondifferential if it is unrelated to 
the occurrence or presence of disease; if the misclassification of exposure is different for 
those with and without disease, it is differential. Similarly, misclassification of disease 
[outcome] is nondifferential if it is unrelated to the exposure; otherwise, it is differential." 
 
4.2.2 Random error 
 
Random error is associated with variations resulting from chance. It occurs because 
estimates in epidemiological studies are based on samples, and there are different degrees 
of accuracy in how each single sample reflects the population at large.  Random error is 
usually associated with three factors: 
 
o the sample size 
o the degree of inter-individual variability in the sample 
o the magnitude of observed differences (when the observed difference in outcome 
between the groups increase, the likelihood of it being caused by chance decreases) 
 
Random error is unpredictable but it can be reduced by using larger sample sizes and 
efficient statistical analyses. Estimation of random error can be done through two methods: 
p-value, or hypothesis contrast test, and confidence intervals. 
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P-value indicates the probability of observing differences between the groups, even if the 
null hypothesis of no difference between them was true. Hence, the smaller the p-value, the 
lower probability that the observed difference was a result of random error. Most 
commonly, differences with a p-value <0.05 are considered statistically significant. 
However, this criterion is arbitrary, as a p-value of 0.04 means there is a 4% chance of 
finding the observed difference due to sampling variability, and 0.06 indicates a probability 
of 6%. Practically, the difference between 4% and 6% probability is very small, but only 
the first value would be considered statically significant.  
 
Confidence intervals (CIs), just as p-values, are derived from the standard error (SE), and 
the two of them are naturally related. CIs can be used regardless of the type of outcome 
measure, and give us a range of values within which we are reasonably confident that the 
true population difference lies. The point estimate is the most likely value based on 
observed data, and a 95% CI can be interpreted such that we are 95% confident that the 
interval contains the true value of the population parameter.  
 
The SE is inversely related to the sample size. As the sample increases in size, the SE 
decreases and, if there is an association, the CI becomes narrower. Based on this, the use of 
CIs when considering whole population data (such as the national cancer register) has been 
debated, since the study population is not a sample of the national population. However, 
even national populations can be considered samples from the world population, and the 
registers are not always 100% complete. Therefore, the use of CI is, as a rule, motivated 
(157). 
 
Both p-values and CI constitute measures of precision in the study There is an ongoing 
debate regarding the advantages and disadvantages of using CIs and p-values, but this 
discussion is complex and lies outside the scope of this thesis. In the included studies we 
have generally reported CIs for estimates from regression analyses and p-values for 
comparisons in descriptive tables.  
 
4.3 INTERNAL AND EXTERNAL VALIDITY 
 
Precision and validity are two important concepts when evaluating the quality of any 
observational study. As previously described, precision is a lack of random error. Validity, 
on the other hand, refers to a lack of systemic error.  
 
Internal validity can be explained as the strength of the inferences from the study, i.e. if the 
study does estimate what it aims to estimate. Are the observed changes in the outcome 
between the groups attributed to the exposure and not to other possible causes?  Lack of a 
control group, or a control group that is not comparable to the exposed group in measurable 
or unmeasurable ways, would compromise the internal validity.  
 
External validity refers to the ability to generalize results of a study to a more universal 
population. External validity mirrors the degree to which the conclusion s of a study would 
be true for other populations, in other places and at other times. High internal validity is 
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considered to be a pre-requisite for high external validity, but is not a guarantee for it. If the 
sample is not representative, the external validity would be low. Thus, the most common 
loss of external validity in observational studies is usually referred to the fact that studies 
involve small samples from a single geographic location or facility (158). 
4.4 OVERVIEW OF STUDY DESIGNS AND METHODS IN THE THESIS 
 
Table 3. Overview of study designs and methods.  
BC – breast cancer, COS – Controlled Ovarian Stimulation, FP – fertility preservation.  


















Girls and women 
undergoing FP 
Women with BC 
undergoing COS for FP 
Women of 
reproductive age 











COS with antagonist 
protocols adapted to 
women with BC 
(addition of letrozole, 
a random start day of 
COS, use of a GnRHa 
trigger) 









FP indicated by 
benign deseases or 
conditions 







Pregnancy and live 
birth rates. Trends in 
choices of FP 
methods over time. 
Number of oocytes 
and embryos 
cryopreserved 






1st October 1998- 1 
December 2018 (FP 
counseling) 
1st January 1995 – 30th 
June 2017 (FP-
counseling) 
1994 – 30th June 
2017 (BC diagnosis) 
Number of 
participants 
31 women with a 




without history of 
cancer (244 
pregnancies) 
1254 female patients 
(852 with oncologic 
indication and 402 
with non-oncologic 
reasons for FP) 




380 cycles with GnRH 
antagonist 
1275 women (450 
exposed to FP and 

















As shown in the table above, all four studies of this thesis are observational studies. 
 
Study I is a cohort study including women who underwent oocyte donor treatments at 
Karolinska University hospital between 2003 and 2015, where information on exposure, 
outcome and other variables of interest had been continuously recorded in the clinical 
registry. The study investigates association between history of cancer as a cause of 
infertility and adverse obstetric or perinatal outcome among women treated with donor 
oocytes.  
 
Study II is a cohort study of girls and women referred for FP to the Reproductive Medicine 
Clinic of Karolinska University Hospital between 1 October 1998 and 1 December 2018. 
This study summarizes the results of 20 years of FP counseling at the center. It assesses 
return rates and utilization rates of cryopreserved specimens during long-term follow-up in 
relation to oncologic vs non-oncologic indications for FP. It also investigates how trends in 
decisions regarding preferred FP-methods have changed over time.  
 
Study III is a prospective multicenter cohort study with national coverage including 610 
women with BC counseled on FP between 1 January 1995 and 30 June 2017 at six Swedish 
regional FP programs. Efficacy of newly introduced potential improvements to COS for FP 
(addition of letrozole, random start of COS, use of GnRHa trigger) was investigated in 
comparison to standard GnRH antagonist protocols. We also report long-term overall 
survival and reproductive outcome in relation to FP-status.  
 
Study IV is a register-based nationwide matched cohort study, where long-term 
reproductive outcome, defined as post-BC live births and performance of ART-treatments, 
were compared among 425 women who had undergone FP at one of Swedish University 
hospitals and 850 comparators with BC but without history of FP, matched on age-group, 
time-period and health care region.  
 
4.4.1 Study I 
 
Study population and data sources  
 
Study I included all cases of oocyte donor treatment performed at Karolinska University 
Hospital between 2003 and 2015 to the women with iatrogenic infertility due to previous 
cancer diagnosis (n women = 31). For the analysis of main outcome, only women with 
deliveries following OD treatments were included (20 women, 25 pregnancies).  A group of 
comparators consisted of women who underwent similar fertility treatment at the same 
period of time (212 women, 244 pregnancies) but did not have any history of cancer. For 
the subanalysis, all OD treatments in the post-cancer group (31 women, 102 treatment 
cycles) were included.  
 
In Sweden, OD treatment has been available since 2003, restricted to university hospitals 
only. Just like other ART-treatments, they are provided within tax-funded health care 
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system to couples with primary infertility, female age < 39 years and male partner <56 
years. Until 2019, OD treatment could only be offered to couples, not to single women. It 
required a strict psychosocial evaluation process, where both potential parents needed to 
prove their good health and potential to take care of the future offspring. To reduce 
maternal and perinatal complications associated with multiple conceptions (159), the rule of 
single embryo transfer is applied to OD-treatments.  
 
Demographic characteristics, data on cancer treatments, OD-treatments and pregnancy 
outcome were collected from the medical records.  Data on treatments using OD were 
prospectively entered to the Reproductive Medicine’s electronic database (LinneFiler®, 
Fertsoft AB, Uppsala, Sweden). Data on pregnancy and delivery were prospectively 




Exposure: history of antineoplastic treatment. 
 
Co-variates considered as possible confounders: maternal age at embryo transfer (ET), 
maternal body mass index (BMI, kg/m2), and smoking at the first antenatal visit. 
 
Primary outcome: obstetric and perinatal outcomes defined by corresponding ICD-10 code 
or record in medical files of Obstetrix®: preeclampsia (PE),  eclampsia, HELLP syndrome 
(hemolysis, elevated liver enzymes, and a low platelet count), pregnancy-induced 
hypertension, placental abruption, preterm premature rupture of membranes (PPROM), 
postpartum hemorrhage of >1000mL, placenta previa, Gestational Diabetes Mellitus, small 
for gestational age, preterm birth (birth before a gestational age of 37 complete weeks) 
further subdivided into extreme (<28 weeks), very preterm (28 - <32 weeks), and moderate 
(32 - <37 weeks), mode of delivery (Cesarean or vaginal), APGAR less than 7 at any point 
during the first 10 minutes after birth, and pH <7 at umbilical arterial blood.  
 
In the subanalysis, exposure was defined as history of radiotherapy to abdomen/ pelvis/ 
total body irradiation. Outocme was defined by corresponding record in LinneFiler® or/and 
Obstetrix®: thickness of endometrium (measured by ultrasonography on the day of embryo 
transfer), pregnancy rate (defined as positive U-hCG per treatment), delivery rate (defined 
as delivery after gestational age of 22 weeks and 6 days), mean gestational age at birth, and 




The associations between the history of antineoplastic treatment and adverse outcome in 
OD pregnancies were calculated using logistic regression, estimating ORs and 95% CIs. As 
there were very few smokers in the cohort, smoking was not included as a confounder. We 
performed complete case analysis, i.e. only observations with complete information on the 
included variables were included in the regression model. Further adjustment for 
intrasibling correlation with a robust estimator of the standard error was performed in order 
to account for the independent data structure (one woman could contribute with more than 
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one observation if she had more than one child).  For the subanalysis, mean values and rates 
were compared. P-value was calculated using Pearson’s chi-squared test for factor variables 
and t-test for the continuous variables. 
 
4.4.2 Study II 
 
Study population and data sources  
 
In Study II we used the data collected prospectively in the electronic database at the 
Reproductive Medicine center (LinneFiler®) regarding clinical characteristics, details of 
ART treatment, and eventual utilization of cryopreserved cells/tissues among women and 
girls referred for FP to Karolinska University Hospital between 1 October 1998 and 1 
December 2018. Using unique Swedish personal identification number, each person in the 
cohort was linked to the Total Population Registry of the Swedish Tax Agency to assess 
overall survival in the entire cohort as of 1 December 2018.  
 




Exposure: oncologic indication for FP as compared to benign indications for FP, and age 
>18 years at the time of FP as compared to the age of 1-17 years. 
 
Detailed data on diagnosis that indicated FP counseling, and data on demographic and 




Primary outcome: return rate for counseling or pregnancy attempt as well as long-term 
reproductive outcome defined as pregnancy and live birth rate (for benign vs malignant 
indications). Trends in preferred FP methods over study period (adults vs children and 
adolescents) were analyzed.  
 
Secondary outcome: outcome of FP cycles aiming at oocyte or/and embryo 
cryopreservation.  
 




The proportion of women who returned for counseling and fertility treatment was 
calculated out of all the women who had undergone FP, were 18-45 years at the end of 
follow-up, and were alive and living in Sweden at least 1 year following FP. The return 
rates of women with malignant and benign indications for FP were compared using logistic 
regression (ORs and 95% CIs) with adjustment for attained age. Pregnancy and live birth 
rates were calculated among women who returned for fertility treatment, and compared 
between malignant and benign indications using chi-square tests.  
 
4.4.3 Study III 
 
Study population and data sources  
 
The study population included women with diagnosis of BC, referred for FP counseling. 
The study subjects were identified from the electronical medical records at six Swedish 
university hospitals with programs for FP, each covering a healthcare region.  
 
Data on demographical and clinical characteristics, as well as the details related to FP-
procedures, were collected from the electronic medical records. The system of electronic 
medical records has been implemented in Sweden since 1997, and the data are registered 
prospectively at the clinical treatment registry at each hospital. Data on overall survival was 
obtained from the Total Population Register of the Swedish Tax agency, using unique 




Figure 7. Flowchart of the study population, Study III. BC - breast cancer, COS - 






Exposure was defined as:  
1. Use of GnRH antagonist protocols with potential improvements (i.e. co-administration of 
letrozole, random start of COS and use of GnRHa trigger) as compared to standard GnRH 
antagonist protocols;  
2. FP treatment as compared to FP-counseling only;  
3. Return for FP counseling/utilization of cryopreserved specimen among women who 
received FP as compared to women who have not returned yet. 
 
Number of oocytes and embryos cryopreserved were defined as primary outcomes. 
Secondary outcomes included return for new FP counseling, treatment, eventual deliveries 




Complete-case linear regression models were used to estimate associations between 
exposure and primary outcome. Overall survival was compared between the groups using 








4.4.4 Study IV 
 
Study population and data sources  
 
The study population included women of reproductive age diagnosed with BC.  
Women who underwent FP at one of seven Swedish university hospitals between January 
1, 1994 and June 30, 2017 were identified in the medical records of each hospital and, using 
their unique personal number assigned to all Swedish residents, further identified in the 
Swedish quality registers for BC. Two matched comparators unexposed to FP were 
sampled for each exposed woman (Fig 8). Data on FP procedures for women with FP were 
obtained from the electronic medical records of each hospital. Additional variables of 
interest could be retrieved by linking the cohort to Swedish population registers (Table 4).   
 






Exposure was defined as receiving FP treatments. 
 
The primary outcome was live birth after the diagnosis of BC. Secondary outcomes 
included reception of ART treatments after BC diagnosis. All-cause mortality was also 
included as a secondary outcome since it is a competing risk in the studied associations. 
Perinatal outcomes were included as a descriptive component. 
 
 33 
Table 4. Swedish population registers used to obtain information on cohort. 
Register Description Years Information retrieved 
Swedish National 
Cancer Register 
Since 1958, six regional cancer 
centers report on all cancer cases, 
and the data includes histological 
type, site and stage of tumor, date of 
diagnosis, eventual date and cause 




date of BC diagnosis, 
age at diagnosis, 
tumor characteristics, 





Quality Register for 
BC 
A population-based register, with 
information on tumor characteristics, 
treatment, and relapse occurrence in 
patients diagnosed with invasive BC 





registers for BC, for 
regions West and 
Stockholm-Gotland  
Prior to 2008, data on tumor 
characteristics, treatment details and 
relapse occurrence for all cases of 
invasive BC were reported to the 




The Total Population 
Register  
It contains data on life events 
including birth, death, marital status 
and migration; maintained by the 
government agency Statistics 
Sweden. Updates are transmitted 
daily from the Tax Agency to the TPR. 
1994-
2018 




Generation Register  
It contains connections between 
index persons (registered in Sweden 
at some time since 1961 and born in 




year of live births 
Longitudinal 
integrated database 
for health insurance 
and labor market 
studies (LISA) 
It is maintained by the government 
agency Statistics Sweden and holds 
annual registers since 1990, 
integrating existing data from the labor 
market, educational and social sector. 
1994-
2017 
educational level and 
country of birth 
The Medical Birth 
Register 
It includes data on all births in 
Sweden since 1973, reported 
information comes from medical 
records from the prenatal, delivery 
and neonatal care. 
1994-
2017 
date, perinatal and 
obstetric outcomes of 
post-diagnosis live 
births 
The National Quality 
Registry for Assisted 
Reproduction 
It was started 2007 and contains data 
on all ART-treatments in Sweden, in 
both public and private IVF clinics, 





treatment details and 
outcome of all ART 
cycles 




Delayed-entry Cox proportional hazard models, with the time since diagnosis as the 
underlying time scale were used to estimate HR and 95% CI for live births, ART and all-
cause mortality. The cumulative incidence of post-BC childbirths and ART treatments in 
exposed and unexposed women were estimated non-parametrically in the presence of the 





5.1 STUDY I 
 
Study I examined the association between history of cancer treatment and risk for 
pregnancy complications in a cohort of 232 women treated with OD at Karolinska 
University Hospital. The main results of this study were:  
 
 20 women with the history of cancer (exposed) and 212 women without cancer 
history (unexposed) achieved 25 vs 244 live births after treatment with donated 
oocytes, respectively; there were no statistically significant differences in the 
baseline characteristics between these two groups. 
 
 In multivariable adjusted analysis, women with the history of cancer had increased 
incidence of preterm births (aOR 5.54, 95% CI 2.01-15.31). The mean gestational 
week at delivery was 36.9 in the exposed group and 39.3 in the unexposed group. 
Stratifying for extreme (<28 weeks), very (<32 weeks), and moderate (<37 weeks) 
prematurity, the risk for very preterm birth was observed to be several fold 
increased in the exposed group (aOR: 17.4, 95% CI: 3.99–75.79), while the 
difference in incidence of extreme and moderate preterm birth was not significant 
between the groups (OR: 3.35, 95% CI 0.33-33.93 and aOR: 2.92, 95% CI 0.88-
9.66). For extreme preterm birth, only unadjusted analysis was performed (due to 
only 1 case in the exposed group).  
 
 The incidence of PPROM did not differ significantly between the groups (aOR 3.85, 
95% CI 0.96-15.42). 
 
 Compared to women without cancer history, survivors of cancer had a higher 
incidence of PE (aOR 2.79, 95% CI 1.07-7.34). However, the risk for hypertensive 
disorder of pregnancy (including both PE and pregnancy-induced hypertension) did 
not differ significantly between the groups (aOR 1.8, 95% CI 0.69-4.69).  
 
 Cesarean was the mode of delivery in 48% of women in the exposed group and 43% 
in the unexposed group, compared to 17% of all deliveries in Sweden (160).  
 
 PPH, defined as bleeding over 1000 mL, occurred in 32% vs 27% of women in the 
exposed vs the unexposed group, compared to a general rate of about 10% in 
Sweden (160).  
 
 The incidence of Apgar score below seven during first 10 minutes after births and 
the need of care at the Neonatal Intensive Care Unit (NICU) did not differ between 
the groups (aOR 2.40, 95% CI 0.24-24.46 and aOR 1.14, 95% CI 0.36-3.61). 
 
In a subanalysis in Study I, differences in reproductive outcome among women with and 
without history of radiotherapy (RT) (to abdomen, pelvis/total body irradiation) were 
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investigated in a cohort of 31 women with oocyte donation treatment indicated by 
iatrogenic infertility after cancer treatments. The main results of this subanalysis were:  
 
 15 women with the history of RT have undergone 47 treatment cycles with donated 
oocytes (26 fresh embryo transfers (ET) and 21 frozen embryo transfers, FET) 
compared to 16 women without history of RT, that have undergone 55 cycles, 26 
ETs and 29 FETs. 
 
 Among women with the history of RT, mean thickness of endometrium at treatment 
cycle was 7.4 mm (range 4-12 mm) compared to 9 mm (range 5-14.2 mm) among 
women without history of RT, p-value < .001. 
 
 There was no difference regarding pregnancy rate (23% vs 36%, p = 0.2), live birth 
rate (19% vs 29%, p = 0.3) or delivery per pregnancy rate (82% vs 80%, p = .9) in in 
women with vs without history of RT. 
 
5.2 STUDY II 
 
Study II examined trends over time in choices of FP methods in women and girls with 
oncologic and non-oncologic indications for FP at Karolinska University Hospital. It also 
investigated return rates and long-term reproductive outcome in relation to benign vs 
malignant indications. The main results of this study were:  
 
 Between 1 October 1998 and 1 December 2018, 1254 females (1076 adults and 178 
girls under age of 18) received FP counseling for either oncologic (n=852) or 
benign (n=402) indications, and were included in the study. Of those, 592 vs 285 
females with malignant vs benign indications proceeded to FP treatments.  
 
 The majority of adult women elected cryopreservation of embryos and/or oocytes 
(n=538, 73%) as opposed to cryopreservation of ovarian tissue (n=221, 27%). More 
than a half of women with partner (53%) elected to either cryopreserve unfertilized 
oocytes or to cryopreserve both oocytes and embryos.  
 
 Patients’ choices of FP method have changed over time during the study period. For 
adolescents, cryopreservation of ovarian tissue was the preferred method in the 
2000s, while an increasing number of postmenarchal girls have elected to undergo 
controlled ovarian stimulation for cryopreservation of oocytes in recent years. Also, 
since 2014, cryopreservation of oocytes has replaced cryopreservation of embryos 
as the most popular method of FP among women with partner.  
 
 By December 2018, the mean time of follow-up was was 6.1 ± 4.8 (0‐19) years 
since FP consultation. Ninety‐seven patients had died (91 in the group with 
malignant FP indications, and 6 in the group with benign FP indications),  21 had 




 During the follow-up, 27% of women aged 18-45 who had undergone FP for 
oncologic vs non-oncologic indications, and were alive and living in Sweden at least 
1 year following FP, returned for a new reproductive counseling, additional FP or to 
attempt pregnancy. Patients with malignant FP indications had a slightly lower 
likelihood of returning for counseling (OR 0.72, 95% CI 0.51-1.0) and a 
significantly lower likelihood of returning for pregnancy attempt (OR 0.41, 95%CI 
0.27-0.62) when compared to patients with benign indications. 
 
 Overall, utilization rates among women who were alive and of childbearing age, and 
had a follow-up of at least one year after FP, were 29%, 8% and 5% for embryos, 
oocytes and ovarian tissue, with pregnancy rates of 66%, 54% and 25%, and live 
birth rates of 54%, 46% and 7% respectively.  
 
 Among women who returned for fertility treatment during follow-up (53/402 vs 
75/592 of women with benign vs malignant FP indication), overall live birth rate 
was 66% vss 34% (p< .001), with live birth rate  after use of cryopreserved 
specimen 47% vs 21% (p=.002). 
 
5.3 STUDY III 
 
Study III examined efficacy of certain novel approaches to controlled ovarian stimulation 
aiming at oocyte and/or embryo banking in the setting of FP programs for young women 
with BC, and investigated long-term outcomes including reproductive outcome and overall 
survival in women who did vs did not proceed to FP after initial FP counseling.  
The main results are presented below:  
 
 Of 610 who received FP counseling indicated by BC diagnosis, 468 women 
proceeded to FP treatment (FP group): 41% of them aimed at oocyte banking, 28% 
at embryo banking, 15% at shared oocyte and embryo banking, and 14% at 
cryopreservation of ovarian tissue. In some few cases, a combination of FP methods 
was practiced. 
 
 Women in the FP group were significantly younger and had lower parity than those 
who did not proceed to FP after counseling.  
 
 Of 401 COS cycles performed, 380 used a GnRH antagonist and were included in 
the main analysis. Protocols with concurrent use of letrozole were applied in 59% of 
the cases (n=224), and in 43% of these cycles final oocyte maturation was induced 
with GnRHa as opposed to a standard hCG trigger. As opposed to conventional 
start, random start was practiced in 53% of all GnRH antagonist cycles. 
 
 In letrozole vs no-letrozole group, the number of total and mature oocytes retrieved 




 When GnRHa was used as a maturation trigger in letrozole-cycles, number of 
oocytes retrieved (p<.05) and embryos cryopreserved (p<.005) was higher than in 
the group with conventional hCG trigger.  As women in the group with GnRHa 
trigger had significantly higher AFC and AMH (confounding by indication), we 
performed an additional complete case analysis adjusted for AFC and AMH; 
association between GnRHa trigger and higher number of retrieved oocytes was not 
confirmed, but the one between GnRHa trigger and higher number of cryopreserved 
embryos was still statistically significant (p=.04).  
 
 The number of retrieved oocytes, as well as the number of cryopreserved oocytes 
and embryos were similar in COS cycles with random vs conventional start, but 
higher total dose of gonadotropins was required in women undergoing random-start 
COS (p<.001).  
 
 Women who proceeded vs did not proceed to FP after counseling had similar 
overall survival, with a 5-year survival proportion of 0.94 (95%CI: 0.87-0.97) vss 
0.94 (95% CI 0.91-0.96). No difference in overall survival was found between 
women in COS vs non-COS group either.  
 
 Among women who underwent COS, 5-year overall survival in letrozole vs non-
letrozole group was similar, 0.96 (95%CI:0.91-0.98) vs 0.95 (95%CI:0.90-0.97). As 
the majority of women in letrozole group had ER-positive BC, additional Cox 
regression models adjusted for letrozole alone (Yes/No) and subsequently adjusted 
for ER-positivity (Yes/No) as a complete case analysis (data on ER-status available 
for 280 of 280 women) were tested. There was no difference in overall survival 
between the women in no-letrozole group (reference) and letrozole group (HR 0.96, 
95%CI: 0.27-3.34).  
 
 One-fifth of women who underwent FP returned during follow-up time to either use 
cryopreserved specimens or with a wish of a new fertility counseling, with regard to 
completed BC treatment. Of these women, 26% delivered at least one baby by the 
time of our report, compared to 5% among women who had not (yet) returned and 
5% among women from the no-FP group. 
 
5.4 STUDY IV 
 
Study IV investigated associations between long-term reproductive outcomes and FP in a 
matched cohort of 1275 women, diagnosed with BC in Sweden 1994 - 2017.  The main 
results were:  
 
 Among women with the history of FP at the time of BC diagnosis, 22.8% (97 of 
425) had at least one post-BC live birth after a mean follow-up of 4.6 years, 
compared to 8.7% of women (74 of 850) without history of FP, and with a mean 




 Rate of post-BC live births was higher among women who had undergone FP, when 
compared to women without FP history (aHR: 2.3, 95%CI: 1.6-3.3). 
 
 The five-year cumulative incidence of post-BC live births was 19% vs 9% among 
women exposed vs unexposed to FP. After ten years, the cumulative incidence of 
post-BC live births was 41% vs 16%, respectively.  
 
 ART-rates after BC were higher in the FP group, compared to no-FP group (aHR: 
4.8, 95%CI: 2.2-10.7). 
 
 Compared to women who had not received FP treatments at the time of BC 
diagnosis, women with the history of FP had a lower rate of all-cause mortality 
(aHR:0.4, 95%CI:0.3-0.7), with five-year cumulative incidence of death of 5.3% vs 
11.1% in FP vs no-FP group.  
 
 Mean time from diagnosis to live birth was 4.5  2.5 years (range 1-13) in the 
exposed and 4.5  2.3 years (range 1-13) in the unexposed group. 
 
 Among the women who gave birth after BC, 77.1% in the exposed group and 33.9% 
of those in the unexposed group were nulliparous before their cancer diagnosis 
(p<.001). Women with FP were also more likely to have more than one child after 






6.1 STUDY I 
6.1.1 Main findings and interpretation 
 
Results of Study I suggest that in pregnancies achieved using donated oocytes, women with 
a history of cancer have a higher risk of perinatal complications, particularly preterm birth 
and PE, than women without cancer history. In a subanalysis of reproductive outcome after 
OD cycles, the history of RT to abdomen/pelvis/total body was associated with thinner 
endometrium, when compared to the history of treatment with other modalities. These 
findings suggest that already known increased risk for adverse perinatal outcome in 
pregnancies with donated oocytes may potentially be amplified in women with previous 
cancer treatments.  
 
6.1.2 Methodological considerations and validity 
 
To our knowledge, that was the first study investigating specific maternal and perinatal 
risks in OD pregnancies among women with a history of cancer. With that said, it was not 
without limitations.  
 
As this was an observational study, lacking randomization, participants in the exposed and 
the unexposed group could differ systematically due to other reasons than exposure. The 
two groups were comparable at baseline (first antenatal visit) as regards to age, BMI and 
smoking habits. The treatments were performed at the same medical unit. Like all other 
candidates for OD treatments in Sweden, all the participants in this study went through the 
same procedure of physical and psychosocial screening to ensure that they did not have any 
apparent contraindications for pregnancy. Though the deliveries occurred at more than one 
hospital, all of them were tertiary hospitals in Sweden with the similar standard of care, and 
theoretically, there should not be any systematic difference between the exposed and 
unexposed group regarding the choice of the hospital. All these facts would support the 
comparability of the groups at baseline. 
 
Logistic regression models were used to analyze the main outcome. The confounders 
considered a priori for inclusion in multiple logistic regression models were maternal age, 
maternal BMI, and smoking status at the first antenatal visit. Smoking status was missing in 
6/25 vs 0/244 cases in the exposed vs unexposed group, and among cases with smoking 
information there were very few smokers in either group (5.3% vs 2.9%). Our analyses 
were complete case analyses, and missing data on smoking in 24% of cases in the exposed 
group would result in losing of 24% of exposed participants. We therefore adjusted only for 
age and BMI. Post-publication sensitivity analysis, adjusting for smoking, maternal BMI 
and age among the cases with complete data, made the observed increased risk for PE 
among women with previous cancer non-significant, aOR 2.46 (0.89-6.80), while the 
results for preterm birth were more robust, with OR 4.70 (1.51-14.63) after this additional 
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adjustment. Similarly, stratifying on the smoking status, and including only non-smokers 
with complete data in the analysis (22 cases among women with previous cancer and 216 
among comparators), results for PE were no longer significant, aOR 2.60 (0.93-7.25), while 
the difference in risk for preterm birth remained, aOR 5.03 (1.61-15.74). 
 
Information bias, or more precisely non-differential misclassification, could have occurred 
as we did not have data on the age of oocyte donors or the oocyte quality – variables with 
the potential impact on outcome.  
 
Women undergoing OD treatments in Sweden have to fulfill certain requirements on their 
physical and psychosocial condition, and be under the age of 40 at time of starting the 
treatment. This fact increases the internal validity of the study, making the exposed and 
unexposed group similar to each other on other characteristics than exposure status. At the 
same time, it may also introduce selection bias and reduce generalizability/external validity 
of our results to other settings, not having the same rigorous procedure of selecting 
candidates for OD treatments.  
 
The major limitation of this study was beyond any doubt its small sample size and few 
events. As it has been previously mentioned, random error is usually associated with three 
factors: the sample size, the degree of inter-individual variability in the sample, and the 
magnitude of observed differences (when the observed difference in outcome between the 
groups increases, the likelihood of it being caused by chance decreases). The wide CIs 
reflect a large random error and indicate that the precision is low.  
 
The sample available for subanalysis of reproductive outcome after OD in cancer survivors 
with and without history of RT was even smaller. Data were missing on certain important 
variables, such as detailed information on cancer treatments. Due to the small sample size, 
adjustment for possible confounders could not be performed, and groups with observed 
statistical difference in age, BMI and endometrial thickness were directly compared. 
Therefore, the observed differences in endometrial thickness should be interpreted with 
caution, although they were consistent with results of previous studies in the field.  
 
6.1.3 Clinical and scientific context   
 
An increased risk of PTB in OD pregnancies is well-documented (161-163). In our cohort, 
the incidence of PTB was 9% among women with a history of cancer and 36% among 
women without cancer history. Stratifying for extreme, very preterm and moderate preterm 
births, statistically significant differences in outcome were found for very preterm births. It 
is difficult to find plausible physiological explanation for an increase in very preterm births 
only, and not in other types of PTB. This finding is probably related to the problem of 
stratifying outcome in already a small sample, and the observed difference in OR for all 
preterm births is more robust. In general, spontaneous preterm births (i.e. births that follow 
spontaneous preterm labor and PPROM) are often regarded as a syndrome, with the most 
common causes being infection or inflammation, vascular disease, and uterine 
overdistension (164). For indicated preterm births, common reasons include pre-eclampsia 
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or eclampsia, and/or intrauterine growth restriction (164). Theoretically, increased level of 
anxiety for complications among women with history of cancer and their obstetricians 
could make them more prone to opt for planned preterm delivery to avoid further potential 
risks, but no cases of iatrogenic PTB without clear indication or pathology were found in 
the cohort, and most cases of PTB were related to PE and PPROM. Difference in PPROM 
between the groups did not reach statistical significance, but it would be of value to test for 
it in a larger cohort. In a recently published cohort study from Sweden, being to our 
knowledge the largest study on this topic so far, significantly higher risk of being born 
preterm has been observed among children of female cancer survivors (OR 1.48, 95% CI 
1.39-1.59) (165). The reason for increased risk of PTB in this population is most probably 
multifactorial. As correctly noted by Carg et al., much of the research in the field of 
oncofertility has so far focused on gonadotoxic effects of anti-neoplastic treatment on 
ovaries (166). Meanwhile, injury to a highly mitotic tissue like endometrium may also 
affect fertility and obstetric outcomes, as endometrium can be central to embryo 
implantation and utero-placental exchange. Compromised blood supply to endometrium 
and myometrium and/or fibrosis of uterus as sequalae of radiation, resulting in deficient 
placentation and remodeling during pregnancy, are among proposed explanations to PTB 
and other pregnancy complications in cancer survivors.  
 
In a meta-analysis from 2016, risk of developing hypertensive disorders of pregnancy in 
OD pregnancies compared to ART-pregnancies with autologous oocytes was found to be 
significantly increased (OR3.92, 95% CI 3.21-4.78) (167), consistent with results of other 
studies reporting on increased rate of pregnancy-induced hypertensive complications 
compared to both IVF/ICSI and spontaneously conceived pregnancies (141, 161, 168). 
Complex immunological interaction in the fetal-placental unit is often discussed as a 
possible explanation (169, 170). Swedish population-based matched cohort study from 
2019 found significantly increased risk of pre-eclampsia in survivors of childhood and 
adolescent cancers, when compared to an age-matched comparison group without cancer 
history (OR 3.46, 95% CI 1.58-7.56) (171). Results of previous studies in this area have 
been conflicting, with association observed in some studies (133), but not in others (172, 
173). Possible explanations for increased risk of PE in cancer survivors include the fact that 
survivors of childhood cancers more often suffer from obesity (174), with obesity being one 
of the important risk factors for PE (175). Besides, injury to endometrium as a result of 
chemo- and/or radiotherapy, discussed in the previous paragraph, could also affect 
implantation and development of utero-placental unit, potentially resulting in increased risk 
of pre-eclampsia.  
 
The findings of this study add to the existing knowledge on increased perinatal 
complications of pregnancies with donated oocytes, suggesting an amplified risk for PE and 
PTB in women previously treated for cancer when compared to women without cancer 
history. Still, perinatal outcome in the studied group in general were reassuring, and the use 
of OD to achieve pregnancy in women with iatrogenic ovarian failure related to history of 
cancer should be encouraged. As the sample size was small, future studies to confirm 
observed associations are needed, and if confirmed, potential clinical implications could 
include update of guidelines for surveillance of pregnancies in this specific group. Timely 
initiating of available measures to reduce risk of PE and PTB, combined with 
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individualized screening routines aiming at early detection of elevated blood pressure, 
proteinuria, and warning signs for PTB could be some of the possible steps to reduce 
morbidity.  
 
6.2 STUDY II 
6.2.1 Main findings and interpretation 
 
This study presents over a 20-year long experience of a FP program covering Stockholm’s 
healthcare region, with around 2 million inhabitants. In recent years, cryopreservation of 
unfertilized oocytes became an increasingly popular FP-method both among post-pubertal 
girls, and among women in committed relationships. Previously, the former group most 
often elected cryopreservation of ovarian tissue, while the majority in the latter group opted 
for cryopreservation of embryos. This trend reflects recognition of oocytes’ 
cryopreservation as a clinically established method in 2013, as its efficacy has been proved 
in FP programs worldwide (176). Moreover, it highlights the reproductive autonomy this 
FP method provides to females, as Swedish law states that the partners must be in a 
relationship at the time of using cryopreserved embryos.  
 
During a long-term follow up, return rates for attempting pregnancy and live birth rates, 
both overall and related to FP, were lower in women with previous oncologic FP 
indications compared to women with benign FP indications. That could be related to the 
need to postpone pregnancy attempts for several years after certain cancer diagnoses, and 
also to an increased level of concern in both women and their doctors that pregnancy may 
adversely affect prognosis for disease-free survival. However, the need for FP counseling 
and FP procedures has been high over years in both groups. Summarizing experiences from 
a 20-year period in one of the Scandinavian largest FP programs, this study makes 
particularly clear the importance of clinical and scientific achievements in the field of 
oncofertility for the patients’ choices of FP methods, and for their opportunities to 
experience biological motherhood.   
 
6.2.2 Methodological considerations and validity 
 
Study II was a prospective cohort study, with certain weaknesses and strengths related to its 
design.  
 
Its large sample size, broad spectrum of FP indications included, long follow-up and use of 
cross-link data on overall survival and migration from a population-based registry makes it 
in many ways unique in comparison to other studies evaluating outcome of FP-programs.  
 
The standardized counseling procedure, clear guidelines for referral to FP available on 
institutional and internal webpages, standard operating procedures following national 
guidelines for FP can all be considered as measures to ensure comparability between the 
exposed and unexposed group, i.e. females with malignant vs benign FP indications. Still, a 
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potential cause of selection bias could have occurred during the referral process, where FP-
counseling and FP-treatments were not offered to the sickest patients, resulting in a so-
called “healthy FP” selection bias. That could affect the exposed group more than the 
unexposed, as it lies in the nature of malignant diagnoses that the course of the disease can 
be dramatic with quick deterioration of the health status, thus affecting comparability of the 
groups. It could also affect the cohort in general, reducing generalizability of the results.  
 
Factors associated both with oncologic indications for FP and with the return rate to FP-
clinic could bias the study results if not adjusted for (confounding). Women with 
oncological FP-indication were significantly older at baseline, and also older at the time of 
return for fertility treatment. Therefore, ORs for return rate were adjusted for age. Other 
potential confounders that we could not adjust for include parity at FP-counseling, smoking 
status and socioeconomic characteristics.  
 
Information bias could have occurred at collecting of data on reproductive outcome. Data 
could be missing for patients who conceived spontaneously, or chose to proceed to fertility 
treatments at other centers or abroad. This bias would be by its nature non-differential, 
resulting in underestimating pregnancy and live birth rates in the cohort. 
 
Precision of the study can be regarded as high in the context of other studies of FP-outcome 
due to the relatively large sample size and relatively high prevalence of outcome, reflected 
by the narrow CIs. However, adjustment to several potential confounders was not possible, 
as mentioned above.  
 
External validity, on the other hand, reflects ability to generalize results of a study to a 
more universal population. As previously mentioned, possible “healthy FP” selection bias 
could theoretically affect generalizability of our results. Moreover, in countries where 
medically motivated FP-procedures are not included in the public tax-funded healthcare 
system, economical barriers would result in different characteristics of the populations 
referred for FP-counseling compared to Sweden, therefore reducing generalizability of our 
results to these populations. Another factor that may affect external validity is that 
surrogacy with use of a gestational carrier is not allowed in Sweden, in contrast to some 
other countries, where return rate for pregnancy attempts may thus be higher than those 
observed in our study, and differ less from those in women with benign FP-indications. 
 
With all that said, with the study being an analytical observational study, some of its value 
in the clinical context comes from its descriptive components. The field of oncofertility is 
still young, and some questions that may arise during FP-counseling can yet be answered 
only by referring to certain experiences described in the literature. 
6.2.3 Clinical and scientific context 
 
The importance of providing patients with center-specific information on FP experience has 
been emphasized in other studies (177), mainly with regard to the fact that the published 
results are usually coming from the centers with the highest pregnancy rates, and therefore 
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can be difficult to generalize to centers with less experience. First and most, this study 
provides important data for FP-counseling of girls and women in Sweden, where FP 
programs follow national guidelines. However, with certain reservations, they can also be 
extrapolated to other milieus.  
 
A trend over increasing popularity of cryopreservation of oocytes as the preferred FP 
method, both among post-pubertal girls and among women in committed relationships, was 
observed in this study.  The main advantage of cryopreservation of mature oocytes when 
compared to embryos is that this method guarantees woman’s reproductive autonomy in the 
future, preserving her ability to choose a partner for procreation at the time she decides to 
attempt pregnancy (178). The efficacy of re-transplantation of ovarian tissue was compared 
to the use of vitrified oocytes in a prospective cohort study from 2018 (179); no statistically 
significant differences were found in pregnancy and live birth rates. In a recently published 
study, involving 60 patients after transplantation of ovarian tissues, pregnancy rate of 50% 
and live birth rate of 41% were reported (180). Evaluating oocyte vitrification outcomes in 
the largest series today, Cobo et al. reported a cumulative live birth rate of 68.8% vs 42.1% 
in women ≤35 years of age in women with elective FP vs oncologic FP indications (181). 
Caution should be taken when comparing these rates, as the populations and follow-up time 
may be different. However, in general, outcomes of both methods are reassuring, as also 
confirmed by the fact that since 2019, American Society for Reproductive Medicine 
considers ovarian tissue cryopreservation to be an established, no longer experimental, FP 
method (42). In our study, we also hypothesize that women who return for re-
transplantation of ovarian tissue may require longer time from FP to pregnancy attempt, as 
they usually are younger at the time of FP, and the procedure in itself requires more time 
and recourses than a pregnancy attempt with thawed oocytes or embryos.  
 
Lower return-, pregnancy- and live birth rates in women with oncologic FP-indications, as 
compared to the women with benign indication in our study, are of interest.  In a large 
cohort study of women who had their oocytes vitrified for FP, return rate to attempt 
pregnancy, implantation rate, ongoing pregnancy- and live birth rate were lower for onco-
FP patients, when compared to patients with elective FP (181). The effect of sole presence 
of cancer on live birth rates could though not be confirmed by the adjusted OR in a binary 
logistic regression analysis, while age was found to strongly affect outcome. Still, the 
authors argued that the lack of confirmation of association between previous cancer 
diagnosis and poorer reproductive outcome in that analysis could be explained by a smaller 
number of cancer patients returning to use their oocytes. With reference to the hypothesis 
from the 1970s, that cancer could be viewed as a systemic disease (due to altered 
equilibrium for homeostasis in the whole organism), rather than a local disease (182), the 
authors emphasized the importance of further studies analyzing possible association 
between history of cancer and IVF outcome (181). In our cohort, reproductive outcome 
after FP with oncological indications was observed to be not as good as that after FP 
performed for benign indications, which could be consistent with the theory that 
reproductive outcome after FP may be affected by the underlying malignancy at the time of 
FP. Difference in long-term reproductive outcome could theoretically also be explained by 
the effects of anti-neoplastic treatments (116). However, as the evidence in that fields is so 
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far scarce, possible correlation between previous cancer and long-term reproductive 
outcome after FP needs further investigation. 
 
6.3 STUDY III 
6.3.1 Main findings and interpretation 
 
Results of Study III support the premise that recently introduced approaches to COS 
protocols for FP in eligible women with BC are efficacious and safe. Overall survival was 
used as a proxy of safety in this study, and the observed rates did not differ between women 
with vs without history of FP treatments. However, as the survival rates for BC are high, 
and hopefully will continue to increase, the rate of BC recurrence would be a better 
measure of safety. It should be investigated in relation to FP in future studies.  
 
6.3.2 Methodological considerations and validity 
 
Just as the previous studies discussed in this thesis, this was a prospective cohort study. It 
included data from 6 university hospitals with FP programs in Sweden, covering large 
healthcare regions, together covering the whole country.  
 
The national coverage and large sample size were the main strengths of this study. Due to 
the hormone responsiveness of even the ER-negative BC (183), it would not be ethical to 
randomize women to letrozole vs non-letrozole group; therefore, prospective cohort design 
was chosen for the study.   
 
The risk of selection bias in this study was low because FP in Sweden is provided within 
tax-funded healthcare system, with full-population coverage and equal access. On the other 
hand, when it comes to FP, there is always a risk of “healthy FP” selection bias – that is, 
that women who proceed to FP are healthier or feel healthier, and therefore are more likely 
to proceed to FP after counseling. In contrast, women who are more affected by the disease 
choose - or get advised by their medical providers - to skip additional medical procedures 
not related to the treatment of their disease.  
 
As a rule, all potential confounders included in the regression modeling were selected a 
priori based on their known association with both the exposure (type of COS protocol; or 
FP) and the outcome (number of oocytes and embryos cryopreserved; live birth or overall 
survival).  
 
There were certain problems with missing data in the study. Important possible 
confounding variables for the main analysis of the efficacy of different approaches to COS 
had substantial proportions of missing values; BMI (21%), AFC (58%), AMH (56%).  
 
Building a regression model to control for possible confounding in our analysis of 
reproductive outcome in Table 2 (in relation to the type of COS-protocol), we only adjusted 
 
 46 
for age as a clear confounder. Including BMI, AFC and AMH would have resulted in a loss 
of a huge proportion of study subjects. We reasoned that there were no differences in BMI 
between the groups at baseline, regarding available data, and assumed that the observations 
were missing completely at random.  
 
Type of BC is a variable that could have affected exposure (type of COS protocol, at least 
when it comes to letrozole vs non-letrozole group), but not the outcome (number of oocytes 
and embryos cryopreserved), and therefore, cannot be considered to be a confounder for 
this analysis.  Concerning the overall survival, there is nevertheless a possibility that ER-
status is associated with overall survival and that ER-status potentially confound the (non-
significant) association between letrozole usage and overall survival. 
 
To rule this out, we have estimated a series of Cox regression models adjusted for letrozole 
(Yes/No) alone and subsequently adjusted for ER-positivity (Yes /No). The results from the 
models are shown below: 
 
Table 5. Cox regression models adjusted for letrozole (Yes/No) alone and subsequently 
adjusted for ER-positivity (Yes/No). 






















































Because the data on ER-status were not available for 100 women (out of the 380 included 
in the overall survival analysis presented in the manuscript), a complete-case analysis for 
women with non-missing information on ER-status was first conducted (model 2) for 
comparison with the adjusted results (model 3). There was no significant difference in 
overall survival between women in the letrozole-group (HR 0.96, 95%CI: 0.27-3.34), 
compared to women who underwent COS without letrozole (reference). 
 
“Confounding by indication” is a term used when a variable is associated with the exposure 
status and may also affect the outcome. AMH and AFC differed significantly between the 
group with GnRHa- vs hCG-trigger, and could indeed be considered to be confounders by 
indication (GnRHa is often preferred when there is a higher risk of OHSS, e.g. in patients 
with high AFC or AMH). In clinical setting, the use of GnRHa or hCG had mainly 
depended on the preference of the physician that planned the day of oocyte retrieval. Some 
of the physicians are today familiar with the GnRHa-trigger, but some are not yet at that 
point, and they still prefer hCG. To address this issue, we have performed an additional 
analysis adjusted for AMH and AFC for the women for whom these data were available 
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(complete case analysis, as the data were missing at random). The difference in the mean 
number of cryopreserved oocytes was still significant.  
 
Data on the stage of BC and details of oncological treatment were not available, and 
adjustment for these potential confounders in the survival analysis could not be performed.  
 
Data on pregnancy and delivery rates could be incomplete as some women might have 
moved to other health care regions or searched fertility or pregnancy care abroad. That 
plausibility could have constituted information bias. As the possibility of missing data 
among women unexposed to FP is higher, that would be a differential misclassification to 
consider when interpreting the results, and when designing future studies in that population.    
 
Precision of the study can be regarded as high due to the large sample size compared to 
other similar studies. Our hypothesis was that the new approaches to COS in the setting of 
FP indicated by BC are at least non-inferior in their efficacy when compared to standard 
approaches. The only significant difference we found was a higher number of 
cryopreserved embryos in the group with GnRHa trigger as compared to conventional hCG 
trigger. This result was still robust in a sensitivity analysis adjusted for AFC and AMH. 
Besides that, there were no significant differences in outcome between the groups. But as 
the p-values in some cases were low (cryopreserved embryos in letrozole vs no-letrozole 
group 4.0 vs 5.3, p-value =.075; cryopreserved oocytes in conventional vs random start 
10.6 vs 9.0, p-value =.067), the results should be still interpreted with caution, as the 
probability that observed difference was due to sampling variability was only about 7% - 
not statistically significant, but still worth consideration.   
 
As this was a multicenter study with nationwide coverage, its external validity may be 
regarded as high, at least when it comes to the analysis of efficacy of modified approaches 
to COS. For the analysis of survival and long-term reproductive outcome, a larger and more 
relevant comparison group would be desirable, with complete data on potential 
confounders, in order to increase both internal and external validity.  
6.3.3 Clinical and scientific context 
 
Concurrent use of letrozole is aimed to maintain low systemic estrogen levels during COS, 
and the results of the previous studies examining its impact on oocyte yield were 
inconsistent, with both increased (103), decreased (96, 97) and unaffected (87, 95) oocyte 
yield reported. This inconsistency could depend on relatively small sample sizes and 
differences in COS protocols. Results of our study were consistent with the conclusions 
from the systematic review by Rodgers et al, where addition of letrozole was not associated 
with any decrease in total oocyte yield, with acknowledgement of the limitations of the 
existing literature on COS for FP in women with BC (79).  
 
The finding of increased number of cryopreserved embryos in letrozole group with GnRHa 
trigger (as opposed to hCG-trigger) is consistent with the results of previous studies, that 
indicated higher yield of mature oocytes (82, 83, 159) and embryos(184) in addition to 




Opportunity to initiate COS irrespective of the phase of menstrual cycle is of particular 
importance in the setting of FP for oncological indications, as the time window for FP, 
prior to the start of antineoplastic treatments, may sometimes be very small. A systematic 
review from 2017 concluded, that random start in such settings are associated with shorter 
interval between start of stimulation and oocyte pick-up, and resulted in similar number of 
mature oocytes and cryopreserved embryos (101). We didn’t find any difference in the 
length of COS comparing the two groups, but the number of cryopreserved embryos was 
indeed similar, 4.75 vs 4.78, p=.9.  
 
Even though data on long-term reproductive outcome and overall survival after FP in the 
setting of BC in young women were reassuring in this cohort, and are generally consistent 
with previous studies, these results should be interpreted with caution due to the previously 
discussed methodological considerations, and the fact that existing scientific literature in 
this field is scarce (79, 81). While randomized trials in this context are not feasible, 
population-based data from nationwide registers, including long-term reproductive and 
oncologic outcome, could hopefully help to provide more evidence in this complex and 
important area.  
 
6.4 STUDY IV 
6.4.1 Main findings and interpretation 
 
A higher likelihood of post-BC live births and ART-treatments, and non-inferior all-cause 
survival, was observed in women who underwent FP at the time of BC diagnosis compared 
to women who did not have FP. Successful pregnancy after BC was shown to be possible 
both in women with and without history of FP at BC diagnosis. Future research evaluating 
long-term reproductive outcomes in young women with BC should ideally adjust for 
childbearing intent among those who undergo vs do not undergo FP.  
 
6.4.2 Methodological considerations 
 
As randomized studies of FP vs no FP in women with cancer facing infertility risk are not 
feasible, population-based studies investigating long-term real-world outcomes in 
unselected patient populations can provide valuable information in this context.  
 
This study's key strength was its prospective design and the use of national and population 
registers with essentially complete coverage. It enabled identifying a relevant and well-
defined matched comparison group, and ensured reliable information on reproductive 
outcome, survival, disease-related variables, and some other important confounding factors.  
 
Matching aimed to balance the groups with respect to some key variables that could 
influence the outcome, minimizing variability caused by extraneous factors.  The matching 
criteria included age-group at diagnosis (five-year periods), time of diagnosis (three-year 
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periods) and health care region. Still, comparison of baseline characteristics in the cohort 
reveals significant difference in age distribution between the groups, that can be 
explained by the differences between the groups within each five-year age-group since 
age was strongly related to the likelihood of opting for FP. We were unable to perform a 
tighter matching on age or to include additional matching variables, such as tumor 
characteristics, as the number of eligible comparators were too few. Instead, we took care 
of other confounding variables in our adjusted Cox proportional hazard models. These 
adjusted models included age at diagnosis (21-29, 30-34, 35-42), calendar period (1994-
2007, 2008-2017) and parity at diagnosis (0, 1, ≥2), country of birth (Nordic, non-Nordic), 
educational level (compulsory school, secondary school, higher education), tumor size 
(T0,T1, T2,T3), lymph node metastases (0, 1-3, >3), ER-status (positive, negative), and a 
binary indicator for chemotherapy (neoadjuvant and/or adjuvant vs neither). Including age 
as a continuous variable did not change the results. In addition, there were no statistically 
significant interactions between FP and age (in three categories) when tested using the 
likelihood ratio test. Calendar period was included to indirectly adjust for unmeasured 
factors that have changed over time, such as COS protocols and BC treatment protocols. 
Similarly, educational level and country of birth were included not as confounders per se 
but as markers of other factors that could have influenced the outcomes, such as social 
inequality and health-seeking behavior. 
 
Lack of data on childbearing intent or wish at the time of BC diagnosis was an important 
limitation of our study. It would be logical to assume that women who wish to have 
children after completion of BC treatment are more prone to opt for FP, potentially leading 
to confounding by indication. Additional adjustment of our results for childbearing intent 
would probably rend the difference in birth rate between the two groups smaller. 
 
In studies based on population registers, selection bias can be caused by differential loss to 
follow-up. In our cohort, that was not a case, as 0.7% vs 0.9% of women in FP vs noFP 
have emigrated from Sweden during the study years. Access to FP, cancer treatment, ART- 
treatments, pregnancy- and delivery care is ensured to the population in Sweden within the 
tax-funded healthcare services. This fact further increases comparability between two 
groups, and minimizes the risk of selection bias. Still, discussing the finding of lower 
cumulative incidence of death following BC in women that had undergone FP we argue 
that there could be a “healthy FP effect” - a form of selection bias similar to “healthy 
mother effect” (185) in studies showing better prognosis in women who become pregnant 
after BC diagnosis (122, 123). Even though we have adjusted our analysis for disease-
related and socioeconomic variables, there still could be some prognostic factors that we 
could not capture. As always, to generalize based on a certain outcome, the conclusions 
must integrate representativeness of the sample, completeness of data, statistical methods 
applied, but also existing knowledge about the phenomenon under study (186). Thus, to 
hypothesize that FP itself would provide a survival benefit, would not be logical.  
 
For the first half of the study period (1995-2006), there was no information on ART 
treatments that did not lead to live births. Therefore, it was not possible to study the uptake 
of post-BC ART-treatments for the whole study period – an information bias, more 




For the studied phenomenon, the sample size may be considered large, with precision of 
estimates reflected in relatively narrow 95% CIs. Thus, the risk that the results were 
influenced by random error is relatively low.  
 
Generalizability of the results may be considered as high for the countries with health care 
system standards similar to those in Sweden. Difference in the eligibility criteria for FP 
and/or ART-treatments would naturally affect the ability to extrapolate our findings. Thus, 
the opportunity of surrogacy, allowed in certain countries but not in Sweden, could result in 
a higher rate of post-BC live births, both in women with and without FP history.   
 
6.4.3 Clinical and scientific context 
 
While the practice of FP is spreading, data on pregnancy wish and outcome after cancer 
treatment in women that received FP are yet scarce. What proportion of these women 
would conceive spontaneously, undergo fresh IVF-cycles, use cryopreserved specimens or 
donated oocytes and finally achieve live births has not been yet evaluated in large 
prospective studies with register-based data. In June 2020, a search of PubMed for 
scientific literature written in all languages including the terms “breast cancer”, “fertility 
preservation”, and “reproductive outcome” or “live birth”, from January 1, 2000, until 
March 1, 2020, was performed by the author of this thesis. In a largest reported cohort of 
118 women counseled on FP at the time of BC diagnosis, five-year live birth rate of 27% 
was reported; 29.4% among those who proceeded to FP and 19% among those who 
declined it (187). No nationwide population-based studies comparing long-term 
reproductive outcome in women with vs without FP indicated by BC diagnosis were found.   
 
In general, no relevant control groups have been previously used when evaluating long-
term reproductive outcome in women with a history of FP indicated by anti-neoplastic 
treatments. Long-term reproductive outcomes after FP indicated by cancer have been 
compared to those after elective FP for age-related fertility decline (181), or to those in 
women that received FP-counseling but did not proceed to FP treatments (187, 188), or 
reported as descriptive results in a cohort of women that underwent COS for FP with 
concurrent use of letrozole for cryopreservation of embryos (77).  
 
In one of the first studies of real-life experience in centers for FP, Hulsbosch et al report 
that about one third of patients in remission within five years following the end of treatment 
attempted to become pregnant, with a pregnancy rate of 55% mostly after spontaneous 
conception (189). In 2018, Moravek et al. compared retrospectively long-term outcomes of 
cancer patients who pursued FP (n=204) and those who did not (n=293), with a live birth 
rate of 6.4 % vs 5.5% after spontaneous pregnancies. In addition, 10.3% of women with a 
history of FP returned to use cryopreserved specimens, whereof 51.7% had a live birth 
(190). Reproductive outcomes in relation to the type of cancer were not presented in these 
studies. In a review from 2019, ter Welle-Butalid et al. summarized outcomes of currently 
used FP procedures for oncological indications (63). The reported return rate for embryo 
transfer was on average 23% (range 13-63%). Of women who returned, on average 40% 
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(range 9-75%) had at least one live birth. The proportion of patients returning for embryo 
transfer after prior oocyte preservation varied from 0 to 5%. Those who returned had a live 
birth rate between 33 and 50%. The reported rates differed greatly between the studies 
included in the review, reflecting small numbers of patients and different length of follow-
up.  
 
Study IV, to our knowledge, presents long-term reproductive outcome in to date the largest 
cohort of women with diagnosis of BC at reproductive age, with and without FP at time of 
diagnosis, using prospectively collected data from population-based registers. There is an 
obvious clinical value in reporting long-term reproductive outcome in this population, as 
counseling and decision-making in the settings of FP services for women with BC should 
be based on accurate information regarding chances of post-BC pregnancy and live birth, 
both with and without help of FP. As mentioned, the finding of the improved all-cause 
survival in the FP group should be interpreted with caution. It should not be interpreted as a 
proof of survival benefit of FP in the setting of BC among young women, as any biological 
explanation to such would not be plausible. Still, previous studies using different research 
approaches have indicated at least non-inferior disease-free and overall survival in women 
with BC who undergo FP (79, 190, 191). In this context our findings could be interpreted as 
additional evidence for the results of these previous studies. Further research, preferably of 
prospective design and involving data from population-based registers, including not only 
overall survival but also BC-relapse as a more accurate proxy for safety, is important.  
 
6.5 ETHICAL CONSIDERATIONS 
 
Ethical approval has been obtained for all the studies included in the project. There are no 
economic interests in the studies for responsible persons. The results of all the studies have 
been peer-reviewed. Still, there are several ethical considerations to reflect upon. 
 
Study I and II are prospective cohort studies using the clinical registry of the Reproductive 
Medicine Clinic of Karolinska University Hospital. Study III is a multicenter prospective 
cohort study. Study IV is a nationwide register-based cohort study. Have we chosen correct 
design to our studies? In the hierarchy of research designs, the results of randomized, 
controlled trials are considered to be evidence of the highest grade. In none of the studies of 
this project could we consider this design to be possible because of ethical considerations. 
Even though the advantages of certain stimulation protocols and safety and efficacy of 
different FP methods are still to be examined further, the choice of method / type of 
stimulation today is based on existing state of knowledge about possible risks and benefits, 
and on patients’ preferences. Thus, while choosing the study design, we have tried to 
balance ethical considerations with attempts to increase existing evidence. 
 
Potential risks vs benefits for the women included in the studies 
 
Analysis of unidentified collected data gives no medical risks to the patients included. On 
the other hand, the patients who have already undergone FP treatments would not receive 
any medical benefits either. In further perspective, benefits for the entire patient group may 
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occur from the results of this project (e.g. evidence for efficacy and safety of different FP 
methods). 
 
Reflection on the matter of informed consent 
 
None of the studies clears identity of any woman. Data were analyzed unidentified, and 
only groups were analyzed and compared. Patient consent was obtained at time of FP, 
orally until 2008 and thereafter in writing. None of the patients counselled before 2008 has 
been contacted to obtain written informed consent to participate in the studies, and none of 
the women in the control group, i.e. women without history of FP at the time of diagnosis, 
has been contacted to obtain consent.  
 
Would it be better from an ethical perspective to send information about the planned project 
and request written informed consent? It is difficult to ascertain how high or low the 
response rate would be in such case. Some patients have passed away because of their 
disease. Others that have survived their disease may have more important things in their 
lives than to fill in forms for permission to use their medical data for research that would 
not benefit them personally.  
 
Sending the information about the project and obtaining written consent would mean 
greater work effort for the research group and higher costs. In a world where resources are 
limited, we must prioritize what they are used to. Is it ethical to obtain consent to each 
study that does not involve any medical risks to included individuals when we know that 
the necessary work effort and cost could instead be spent on research? Can potential benefit 
for the entire patient group be related to the fact that some patients may get upset that their 
medical data were included in the study - or in other words - that researchers have entered 
their records without explicitly asking for consent to this in relation to the current study? 
Would they still be sad about it if the results of the research would be of direct benefit to 
them? Would they prefer to regularly receive a bundle of information sheets and consent 
forms for different studies in their mailboxes? Should it be ethical to refrain from research 
if the potential participants would finally refuse to take a stand for each individual study? 
 
Experience from previous studies suggests that women who undergo fertility treatments are 
generally very positive to the fact that their unidentified patient data are used for projects 
aimed at further development and improvement of treatments for infertility. Patients with 
malignant diseases are also motivated to contribute to the research that leads to improved 
diagnosis, treatment and quality of life.   
 
Considering all these arguments, a refrain from collecting individual written informed 
consent from each woman included in the project could hardly be assumed as unethical, in 
the opinion of our research group. The ethics committee was approached to solve this issue. 
Permission was granted for this project, even for the patient groups that had not given 
informed consent previously to use their clinical and registry data for research purpose.  A 
main argument in favor of not requesting informed written consent was that it would be 
difficult to contact women who had not received FP at the time of cancer diagnosis with the 
information about the current project. We cannot know the reason why some women were 
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referred for FP counseling while other were not; maybe they were not interested but it is 
also plausible that they received less information about fertility risks related to their cancer 
treatments, and were not aware of available FP options. Information about the current 
project would thus pose a risk of raising feelings of sadness and loss in those women who 
wish that they had been offered FP options.  
 
Further ethical reflections 
 
Utility and generalizability of the research results are two other important ethical issues. 
Potential usefulness of the results of these studies may be considered high as the practice of 
FP and fertility treatments in young cancer survivors is spreading rapidly. With some 
modifications, results of the included studies may be extrapolated to worldwide populations 
of young cancer survivors planning fertility treatment with donor oocytes (Study I), or 
females planning FP indicated by oncological or non-oncological diseases threatening their 
fertility (Study II), or women of reproductive age diagnosed with BC and concerned about 
if to go for FP or not, and which method of FP and COS in particular to opt for (Study III 
and IV).  
 
Final ethical reflection is that it could be unethical not to perform studies on safety and 
efficacy of different methods of fertility preservation/treatment in young cancer survivors 
when it is known that issues of fertility and reproduction are of high importance to this 






 In pregnancies achieved using donated oocytes, women with a history of cancer 
may have a higher risk of perinatal complications, particularly preterm birth and 
possibly also pre-eclampsia, compared to the women without a history of cancer 
undergoing the same fertility treatment. 
 
 In females with FP indicated by the risk of infertility due to treatment of benign or 
malignant diseases, oncologic indications for FP are associated with lower return 
rates for attempting pregnancy and lower live birth rates. 
 
 Cryopreservation of oocytes has become increasingly popular among women and 
girls consulted for FP during recent years, over available FP options. This trend 
reflects accumulated evidence on the efficacy of this method, and also its’ role in 
protecting female reproductive autonomy.  
 
 Recently introduced approaches to COS for FP in women with cancer are aimed to 
increase the safety and include concurrent use of letrozole, random start of 
stimulation, and use of GnRHa-trigger. Efficacy of these approaches, measured as 
the number of cryopreserved oocytes and embryos, was observed to be at least as 
good as for standard GnRH antagonist protocols. 
 
 FP at the time of BC diagnosis is associated with a higher likelihood of post-BC live 
births and ART-treatments and non-inferior all-cause survival compared to no FP in 
women diagnosed with BC at reproductive age.  
 
 In summary, the use of ART for FP and fertility treatments in eligible young women 




8 FUTURE PERSPECTIVES 
 
In my attempt to explain to my 16-year old son what this thesis was about, he asked: "Why 
don't you just develop an artificial ovary so that you can drip some DNA on it – and voila, 
out comes an egg?" Today, this approach to FP would be more appropriate for science 
fiction, not for a PhD thesis. But, citing Saint Augustine: "Miracles are not contrary to 
nature but only contrary to what we know about nature." Certain approaches to FP may 
indeed sound highly experimental today, but who knows which of them would become 
clinically established in the years to come? Here are some to keep an eye on:  
 
o Activation, growth, and maturation of follicles in vitro. Ongoing research aiming to 
optimize each culture step required for different transitional stages of the follicles 
may result in the development of a new effective option for FP in young female 
cancer patients, and for treatment of POI (192). 
 
o Fresh ovarian tissue transplantation. Immunosuppression, with its inherent side 
effects, would make the procedure ethically and medically questionable. Still, when 
performed in monozygotic twins discordant for ovarian failure (193, 194), or from a 
person who has previously donated bone marrow to the patient (195, 196), it may 
become a good option. 
 
o Artificial ovary. A transplantable artificial ovary's development requires finding a 
suitable matrix to isolate, encapsulate, and graft preantral follicles inside. This step 
would eliminate the risk of reseeding malignant cells at re-transplantation (58, 197). 
Recently, the growth of antral follicles could be observed in a fibrin scaffold with 
autografted human primordial follicles placed in a mouse model – a promising 
finding (198).  
 
o Ovarian stem cells. In recent years, both germline stem cells and somatic ovarian 
stem cells have been reported, questioning the theory that female mammals stop 
producing germ cells after birth (199). Though there are numerous obstacles on the 
way of developing stem cell-based strategies for FP and restoration of endocrine 
function, ongoing research may bring them step-by-step closer to fruition.  
 
While translational research in the area of FP has the potential to offer some mind-blowing 
solutions in the years to come, epidemiological research, and observational studies, in 
particular, will continue to be important in this field of research. They allow investigation 
of long-term outcomes, ensuring the safety and efficacy of new approaches in the settings 
where clinical trials would not be possible due to practical and ethical reasons. 
 
Sweden has, in many ways, a unique system of healthcare, available to the whole 
population, and healthcare registers and population-based registers. It is possible to link the 
data from several registers and build up large cohorts with extensive data on potential 
confounders using the personal identity number assigned to all Swedish residents. Further, 
Nordic countries have similar health care systems as well as similar health and population 
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registers. The use of pooled data from Nordic countries opens even better opportunities to 
overcome the lower power problem that many smaller cohorts may suffer from. 
 
As FP's safety is of utmost importance, the risk of BC relapse after FP, and COS, in 
particular, needs to be investigated further. We plan to examine disease-specific mortality 
and BC-relapse rate in the cohort used for Study IV. An important reservation is that the 
data on relapse are only available for the part of our cohort, as relapse as a variable in the 
National Breast Cancer Register has until recently been reported in only one region in 
Sweden; Stockholm-Gotland. For future studies, the model proposed by Rosenberg et al. 
may be used, with a coding template for relapse in BC based on typical patterns of ICD 
diagnoses in the National Patient Register (200).  
 
The observed association between cancer history and increased risk of PE and PTB in 
women treated with OD, reported in Study I, should be further investigated in larger 
cohorts. Here, register-based data, ideally not only from Sweden but from all Nordic 
countries, would provide perfect opportunities for a study of sufficient power. A possible 
association between specific types of cancer/cancer treatments and increased risk of adverse 
perinatal outcome should also be investigated in this setting. 
 
ESHRE has recently taken an important initiative to increase the quality of FP care. The 
ESHRE Female Fertility Preservation Guideline – the most updated and complete 
document in this field to date – has been published September 2020 (201). Through the 
ESHRE IVF monitoring scheme (EIM), data on FP's short and long-term outcomes are 
collected in an optional module. The registered parameters would include the number of 
interventions, the reason for FP (being medical- or non-medical), and the outcomes 
(number stored and number used). In the long run, these data would provide an excellent 
source for research.  
 
Another essential trace to follow in research related to FP is how young women with cancer 
diagnosis experience fertility-related communication and FP procedures. Here, quantitative 
and qualitative research methods are applied to identify existing gaps and potential for 
improvement in providing FP-services. Short and long-term psychological effects of 





9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Hos kvinnor och flickor kan cancerbehandling med cellgifter, strålning eller kirurgi skada 
äggstockar. Det kan leda till förlorad eller nedsatt fertilitet, dvs förmågan att bli gravid. 
Forskning har visat att möjligheten att skaffa barn är mycket viktig för många unga kvinnor 
som har behandlats för cancer. 
 
Det finns olika vägar att gå för att öka chansen till graviditet efter avslutad 
cancerbehandling. Fertilitetsbevarande åtgärder för kvinnor idag inkluderar möjligheten att 
frysa ner obefruktade ägg, befruktade ägg (embryon) eller små bitar av äggstocksvävnad.  
För att få ett bra antal ägg behövs en stimulering av äggstockar med hormoner. Det tar i 
regel cirka 2 veckor. Därefter, om äggstockarna svarat på stimuleringen, kan äggen plockas 
ut, ev. befruktas och frysas ner. Bitar av äggstocksvävnad kan utförskaffas i samband med 
titthålsoperation och frysas ner. Vid framtida graviditetsönskan kan de sedan re-
transplanteras (återinföras) i kroppen. För kvinnor som har förlorat funktionen i sina 
äggstockar, och inte har några ägg eller äggstocksvävnad i frysen, kan behandling med 
donerade ägg erbjudas i syfte att åstadkomma graviditet.  
 
Det övergripande syftet med denna avhandling var att undersöka effektivitet och säkerhet 
av de ovanbeskrivna metoderna.  
 
I Studie 1 har vi undersökt utfall av 25 graviditeter bland 20 kvinnor med tidigare 
cancerdiagnos och 244 graviditeter bland 212 kvinnor utan cancerdiagnos, samtliga efter 
behandlingar med donerade ägg. Ökad risk för graviditetskomplikationer i form av för tidig 
födsel och pre-eklampsi (havandeskapsförgiftning) observerades bland kvinnor som 
tidigare behandlats för cancer.   
 
Studie II inkluderade 1254 flickor och kvinnor som har fått rådgivning om 
fertilitetsbevarande åtgärder på Karolinska Universitetssjukhuset mellan 1998–2018. 
Samtliga hade antigen onkologiska (cancer) eller icke-onkologiska (godartade) sjukdomar 
vars behandling skulle innebära risk för äggstocksskada. Bland de olika fertilitetbevarande 
metoderna har nedfrysning av obefruktade ägg blivit den mest populära på senare år, både 
bland flickor som kommit in i puberteten och bland vuxna kvinnor. Kvinnor som hade gjort 
fertilitetsbevarande åtgärd p.g.a. cancer återvände till reproduktionskliniker i lägre 
utsträckning, och hade lägre förekomst av graviditeter och födslar, jämfört med kvinnor 
med icke-onkologiska indikationer. 
 
Studie III baserades på uppgifter från reproduktionskliniker vid sex universitetssjukhus i 
Sverige. Sammanlagt 610 kvinnor har fått fertilitetsrelaterad rådgivning i samband med sin 
bröstcancerdiagnos mellan januari 1995 och juni 2017; 468 av dem valde att gå vidare med 
fertilitetsbevarande åtgärd, och 380 stimuleringscykler kunde inkluderas i vår analys. 
Effektiviteten av alternativa protokoll, utvecklade för att öka säkerheten av hormonella 
stimuleringar av äggstockar vid cancersjukdom, visade sig vara minst lika bra som 
effektiviteten av standardprotokoll, mätt i antal obefruktade och befruktade ägg som kunde 
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frysas ner. Den totala överlevnaden skilde sig inte mellan kvinnor som har och inte har fått 
fertilitetsbevarande åtgärder.  
 
Studie IV använde information från svenska befolknings- och hälsodataregister. 
Barnafödslar och behandlingar med assisterad befruktning efter avslutad behandling av 
bröstcancer var betydligt vanligare i gruppen som hade genomgått fertilitetsbevarande 
åtgärd i samband med sin bröstcancerdiagnos (425 kvinnor), jämfört med en matchad 
kontrollgrupp utan fertilitetsbevarande åtgärd (850 kvinnor). Efter 10 år av uppföljning, har 
41 % av kvinnor i den första gruppen och 16% i den andra fått minst ett barn. Det återstår 
att undersöka i fall dessa skillnader kan till viss del bero på att önskan, och inte bara 
förmågan, att skaffa barn skilde sig mellan grupperna. Något negativt samband mellan 
fertilitetsbevarande åtgärder och chansen att överleva har inte observerats.  
 
Användande av IVF-tekniker för fertilitetsbevarande åtgärder och fertilitetsbehandlingar av 
unga kvinnor med cancer, under de förutsättningar som gäller i Sverige idag, förefaller vara 
både säkert och effektivt, enligt våra resultat. Fortsatta studier får undersöka vidare risken 
för återkomst av bröstcancer bland kvinnor med fertilitetsbevarande åtgärder. Koppling 
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